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CHAPTER I 
INTRODUCTION 
 Adult skin consists of two major tissue layers: a keratinized stratified epidermis 
and an underlying thick layer of collagen-rich dermal connective tissue providing support 
and nourishment. Appendages such as hairs and glands are derived from, and linked to, 
the epidermis but project deep into the dermal layer. Because the skin serves as a 
protective barrier against the outside world, any break in it must be efficiently mended. 
WOUND 
A wound is defined as a defect or break in the skin, resulting from physical or 
thermal damage or as a result of the presence of an underlying medical or physical 
condition. When circulation is reduced, blood flow lowered or dermis damaged, the 
wound healing takes longer time and the wound might evolve into a chronic one (Baoet 
al., 2009).Based on the nature and repair process of wounds, they can be classified as 
chronic wounds and acute wounds (Boatenget al., 2008). 
Acute wounds 
Acute wounds are tissue injuries that heal within 8-12 weeks. The primary causes 
of acute wounds are mechanical injuries (friction contact between skin and hard 
surfaces), burns and chemical injuries. (Boatenget al., 2008). 
Chronic wounds 
Tissue injuries which do not succeed to heal in 12 weeks and frequently reoccur, 
usually result in chronic wounds. Chronic wounds arise from a disruption in the order of 
events of the normal wound healing process. 
Chapter-IIntroduction 
 
NLC Based HG for Diabetic wound healing, Reg.No:261211309 Page 2 
 
Broadly, chronic wounds can divide in to five groups: 
 
 Diabetic foot ulcers 
 Pressure ulcers  
 Chronic venous ulcers / venous stasis ulcer  
 Pyodermagangrenosum 
 Vasculitis 
Normal Wound healing process 
To understand the causes of chronic wounds and to have a clear sight on the 
wound management, it is useful to discuss briefly the wound healing process.Wound 
healing process  can be classified into five overlapping phases. 
Haemostasis:When skin is injured, the first response to injury is bleeding. 
Bleeding is an effective way to wash out bacteria that are on the surface of skin. Exudates 
of cells, proteins and fibrinogen are playing an important role in activating clotting 
mechanism in the wound causing the bleeding to stop (Shaw and Martin, 2009). This 
coagulation cascade, ending with a fibrin plug and reflex vasoconstriction, achieves 
haemostatis. The clot dries out and creates a hard surface over the wound that protects 
tissues underlying (Boateng et al., 2008). 
Inflammation: Inflammation is the body’s reaction to injury, starts almost 
simultaneously with the haemostasis. It occurs from between few minutes to up to 24 
minutes after injury. The wound is red, painful and moist under inflammation. The first 
inflammatory respond is performed by the leukocytes, specifically neutrophils, which 
migrate through the endothelium of the local blood vessels to the wound. The later 
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respond is carried out by monocytes, which differentiate to macrophages in the tissues 
after entering by a mechanism similar to that of the neutrophils. These macrophages on 
their turn secrete mediators like cytokine and histamine to the inflammation site and 
results in vasodilatation increased capillary permeation and stimulation of pain 
receptors.(Muzzarelli., 2008; Rhett et al., 2008).and activate phagocytes to enter the 
wound area and engulf dead cells (Boatenget al., 2008).  
Migration: Involves transporting growth factors in the exudates and promotes 
movements of epithelial cells, fibroblasts and keratinocytes to the injured area to renew 
damaged tissue. Cells grow over the wound, under the dried scab and gradually thicken 
the epithelial layer. This step lasts 2-3 days (Helms et al., 2006). 
Proliferation:In the proliferation phase the wound is red and can be moist but not 
exuding. Proliferation can last 5-20 days (Helms et al., 2006). The phase of proliferation 
mainly includes granular tissue formation, neo-angiogenesis, and re-epithelialization.  
A new dermal compound is developed named the granulation tissue which is 
produced by infiltration of fibroblasts, macrophages and vascular tissue fibroblasts, in 
response to growth factors like Plateplet Derived Growth Factor (PDGF). Neo-
angiogenesis, as a result of proliferating endothelial cells, and epithelial layer covering 
the wound are required for the growing granular tissue.  Concurrently keratinocytes 
migrate at the border of the wound over thegranulation tissue in a process called re-
epithelialization. In this way the new outer layer of epidermis is differentiated 
(Muzzarelli.,2008; Boatenget al., 2007). 
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Maturation is the last step of wound healing involves the further remodulation of 
the granulation tissue by its constituent cells.Synthesis of structural proteins, like 
collagen, continues for 6 to 12 months (Muzzarelli, 2008).Collagen fibers are 
strengthening the skin and more capillaries are increasing the blood flow to the wound 
Remolding phase constructs the ceiling. In this phase, maturation of collagen 
type I gets dominant while replacing collagen type III. Remolding phase can lasts up to 2 
years, until 4:1 ratio of collagen I:III achieved, which is same as normal skin tissue. 
(Boatenget al., 2008).The final scar isdetermined by formation of cellular connective 
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tissue and strengthening of the new epitheliumand it is commonly not as strong as the 
skin was before injury, but 70-90% of tensile strength can be expected (Keong and 
Halim.,2009).  
Background of complex wound healing 
Both acute and chronic wounds can be classified as a complex wound if the 
wound has these characterizes: 
 Extensive loss of the integument which comprises skin, hair and 
associated glands 
 Infection which can result tissue loss 
 Tissue death or signs of circulations 
 Presence of pathology 
Impaired wound healing may result from many factors, which can be classified as 
intrinsic and extrinsic factors. 
 Intrinsic factors, or renamed local factors, contain ischemia, infection, 
presence of necrotic tissue and foreign bodies in the wound. 
 Extrinsic factors, or external factors, include diabetes mellitus, cancer, 
chronic disease (chronic renal failure), steroid use, radiation damage and 
malnutrition. Nevertheless, chronic wounds are often a result of a 
combination of these factors (Izadi&Ganchi, 2005). 
Diabetic Wounds 
Diabetes mellitus also increases the risk of prolonged wound healing.Lots of 
complications are associated with diabetic foot due to the sensory, motor and autonomic 
neuropathy and macrovascular disease, which may lead to ulceration, infection, gangrene 
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and eventually amputation. Commonly diabetic ulcers arise from the inability of the 
patient to sense pressure due to the neuropathy, what causes an increase of repeated 
trauma and eventually skin destruction and ulcerations. Beside the neuropathy, patients 
that suffer from diabetes also are at higher risk for peripheral vascular disease.  
The main factors involved in delayed wound healing in diabetes,include more 
rapid apoptosis (cell death), reduced angiogenesis (growth of new blood vessels) and 
impaired lymphangiogenesis, or formation of new lymphatic vessels. 
Moreover, it is assumed that diabetes mellitus is accompanied by a decrease of the 
immunologic defense mechanism, leading to a defect in bactericidal activity 
(Izadi&Ganchi., 2005). Thicker and weaker blood vessel walls and poor phagocytosis by 
neutrophil and macrophage are some of the reasons related for complex wounds in 
Diabetes. (Falanga,2003). 
Wound exudate 
Wound exudate can be described as generic term given to liquid produced from 
chronic wounds, fistulae or other more acute injuries once the haemostasis has been 
achieved. Exudate is actually blood free from red blood cells and components. Exudate 
keeps the wound moist as wound healing process gets faster in a moist environment. 
Exudate provides nutrition for the injured tissue and enhances the migration of epithelial 
cells. Exudate supplies the wound with leucocytes, which control bacterial growth and 
reduce the incidence of infection (Boateng et al., 2008). 
In chronic wounds, an excess production of exudate can create problems. This 
excess can be a result of oedema caused by inflammation. Debridement is the process 
during which slough, eschar and exudate, bacterial biofilms and callus get removed from 
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the wound bed to enhance the healing process. Drastic methods of debridement can be 
painful, therefore use of moisture-donating wound dressings will rehydrate desiccated 
and devitalized tissue and then, separation from healthy tissue will be easier (Fonder et 
al., 2008). 
WOUND DRESSINGS 
Dressings can be classified in a number of ways. They can be classified based ontheir  
 function in the wound (antibacterial, absorbent),  
 type of material employed to produce the dressing (collagen, 
hydrocolloid), 
 physical form of the dressing (ointment, film and gel),  
 traditional and modern dressings.  
TRADITIONAL WOUND DRESSINGS  
Topical pharmaceutical formulations: liquids such assolutions and suspensions or 
semi liquid materials such as ointments and creams.These formulations can be used in the 
initial stages of wound healing, for example asantibacterials (Boateng et al., 2008). 
Traditional dressings: dry materials as cottonwool and natural or synthetic gauzes. 
These dressings are more used in chronicwounds and burn wounds because liquid and 
semi liquid dressings do not remain onthe wound over optimal time (Boateng et al., 
2008). 
Disadvandages of Traditional wound dressings: 
 They can promote desiccation of the wound base, they bind to the wound 
bed and it causes pain and trauma for patients while dressing change. 
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 They do not provide a good barrier against bacterial growth because they 
are susceptible to full thickness saturation with wound fluid (Fonder et al., 
2008). 
 Dry wound healing process would not only delay the wound healing 
process, but can cause further tissue death (Fonder et al., 2008). 
Some of wound dressings can cause allergic reactions when applied to the defectedarea. 
There are three kind of allergic reactions that can appear via wound dressings: 
 Irritant reactions 
 Immediate allergic reaction (contact urticaria) 
 Delayed allergic reactions (contact eczema) (Goossens and Cleenewerck, 
2010). 
MODERN DRESSINGS 
The modern dressing is basedon this concept of a moist wound environment.They 
can stimulate collagen synthesis and promote the angiogenesis for the achievement of 
effective oxygen circulation, regeneration of cells and tissues, and for the lower bacterial 
load.  
Hydrocolloid dressings:Hydrocolloid dressings of colloidal materials associated 
with other materials, for example elastomersand adhesives. These colloidal materials are 
gel forming agents, such as CMC, gelatin andpectin. They appear as thin films and sheets 
and are applied on mildly exuding wounds, suchas pressure sores, minor burns and 
traumatic injuries. (Boatenget al., 2007). 
Alginate dressings: Alginate dressingsappear as freeze-dried porous sheets 
(foams) or as flexile fibers.Alginates containcalcium and sodium salts of alginic acid. An 
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ion exchange occurs between calciumfrom alginate and sodium from wound fluid, 
forming sodium-calcium alginate whichgives a gelatinous mass and can keep the moist 
environment (Fonder et al., 2008). Generally accepted,alginate dressings are used for 
moderately to heavily exuding wounds (Boatenget al., 2007). 
Semi-permeable adhesive film dressings: These wound dressings are made 
from nylon derivatives that can be applied for moistwound healing. They can be applied 
mostly for shallow wounds (Boatenget al., 2008) 
Films:Films are semi-occlusive, permitexchange of oxygen and water between 
wound bed and outside and at the same timethey are impermeable to bacterial and liquid 
contaminants. They provide amoist environment by vapour transmission only. If they are 
applied to wounds withheavy exudate, they can cause fluid trapping (Fonder et al., 2009). 
Foam dressings:These dressings are porous polyurethane foams or polyurethane 
foam films make provision for thermal isolation and are easily applicable.  They 
arehighly absorbent and preferred to gauze in term of pain reduction, patientacceptability 
and nursing time (Boatenget al., 2008). 
Compression dressings: used in the treatment of chronic venous insufficiency. 
These dressings exert theireffect by reducing fluid extravasation into the extracellular 
space to achieve better diffusion ofoxygen and nutrients to the wound (Izadi&Ganchi, 
2005). 
HYDROGEL DRESSINGS 
Hydrogels are swellable hydrophilic materials.Hydrogels can function as a film 
on wounds and in addition keep the wound moist. Hydrogels can be washed off by water 
when change is needed. This will keep the newly made granulation tissue more intact 
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than when removing a dry bandage (Chabyet al., 2007). Hydrogels can be produced in 
two shapes, amorphous or solid sheet/films. If hydrogels are applied to the wound as gels, 
they need a second cover such as gauze. On the other hand if they are applied as films to 
the wound, they can be used both as a primary and secondary dressing(Boateng et al. 
2008).The main features of hydrogels influencing their use in wound treatment are: 
 Shape stability and softness similar to that of the soft surrounding tissues 
 Chemical and biochemical stability 
  High permeability for water-soluble nutrients and metabolites across the 
biomaterial Tissue-interface (Kopecek, 2009). 
Some additional advantages of hydrogels as wound dressings are: 
 Help to the rehydration of dead tissues and increase the healing  
 Suitable rheological properties  
 Convenience in handling&Ease of application 
 Good biocompatibility due to their high water content (Kopecek, 2009). 
 Hydrogels can be the most suitable dressing in debridement stage of a 
chronic wound (Vaneau et al., 2007). 
 Are suitable for cleansing of dry, sloughy or necrotic wounds 
 Do not react with biological reacts ,nonirritant and  non-adherent 
 Cool the surface of the wound 
Hydrogels should be used for dry or low level of exudate wounds. The excess 
moisture can lead to maceration of skin. Hydrogels can be applied and removed with 
minimal trauma and pain from wound bed. Because of the cooling effect that hydrogels 
have on wound bed, they can give a relief feeling to patients (Fonder et al., 2008). These 
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dressings can be used for the treatment of chronic leg ulcers due to their pain reducing 
characteristics(Boateng et al., 2007). 
In general, hydrogels can be prepared from either synthetic polymers or natural 
polymers. An ideal material to be applied to wound should beNontoxic, Biocompatible, 
Enhance cellular interaction and tissue development,biodegradble and bioresorbable 
(Huang and Fu, 2010). 
Hydrogels of natural origin  
Chitosan has been utilized for many medical and pharmaceutical preparations. 
Properties such as being biocompatible, non-toxic and soluble in weak acids make it an 
excellent wound dressing. It is positively charged, is strong tissue adhesive and forms gel 
easily. It has proven to promote adhesion and proliferation in wounds. (Yang et al.,2008). 
And also chitosan can enhance function of leukocytes, macrophages and fibroblasts to 
enhance granulation and rebuilding tissue (Huang and Fu, 2010).  
Hydrogels of synthetic origin  
The synthetic polymers are hydrophobic in nature and chemically stronger 
compared to natural polymers. Their mechanical strength results in slow degradation rate, 
but on the other hand mechanical strength provides the durability as well. These two 
opposite properties should be balanced through optimal design (Tabata, 2009). 
Biocompatibility of synthetic hydrogels is on the other hand not as good as for some 
hydrogels of natural origin, for example chitosan gels (Keong and Halim, 2009).  
 
Chitosan HG on wound healing 
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 Chitosan, By reducing the trans-epidermal water loss, it increases water-binding 
capacity and skin moisture and produces durable moisturizing effect on the skin.  
 It also improves the sensorial parameters and the dermatological compatibility of 
formulations (Dodane and Vilivalam, 1998; Muzzarelli and Muzzarelli, 1998; 
Klingelset al., 1999).  
 The film-forming ability of chitosan assists in imparting a pleasant feeling of 
smoothness to the skin and in protecting it from adverse environmental conditions 
and consequences of the use of detergents.  
 Chitosan was found to be superior to hyaluronic acid as far as lasting hydrating 
effects are concerned (Muzzarelli and Muzzarelli, 1998). 
 Chitosan has been used as an antibacterial and antifungal agent. 
Chitosan improves wound healing 
Catalysis of chitosan degradation is known to be caused by lysozyme, an enzyme 
transported to the wound sites by the inflammatory cells. The abundant lysozyme at the 
wound site would break chitosan to the active N-acetyl-D-glucosamine dimer and 
provide for its sustained release. Because lysozyme acts slowly on chitosan, chitosan 
becomes a continuous source of N-acetyl- D-glucosamine dimers as long as the wound 
contains inflammatory cells releasing lysozyme. The inflammatory reactions and 
therefore the release of lysozyme, continues until the wound is finally healed. 
 
 
 
 
Classification of hydrogels 
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Chemically cross-linked hydrogels: 
Radical polymerization is usually applied to make these polymers. When these 
types of hydrogels come in contact with H2O molecules, they begin to swell up and 
spread their network (Jagur-Grodzinski, 2009).  
Physically cross-linked hydrogels:  
Physically cross-linked hydrogels do not need introduction of an external cross-
linking agent. Cross-linking agents are usually nondegradable and can be toxic and a 
removal of their residuals may be needed before they can be used in biomedical or 
pharmaceutical purpose. The physically crosslinked hydrogels are usually biodegradable. 
Their amorphous hydrophilic phase is held together by highly ordered aggregated chain 
segments held together by secondary molecular forces such as hydrogen bonding, Van 
der Waals forces orhydrophobic interaction (Jagur-Grodzinski, 2009). 
There are several other classifications for hydrogels. They can also be classified based on  
 nature of the network: homopolymer, copolymer, interpenetrating, or 
double networks; 
 physical structure: homogeneous (optically transparent), microporous, and 
macroporous hydrogels; 
 fate in the organism: degradable and nondegradable hydrogels (Kopecek, 
2009). 
 stimuli-sensitivity: Temperature responsive hydrogels, pH responsive 
hydrogels, Analyte responsive hydrogels  
 
SIMVASTATIN ON DIABETIC WOUND HEALING 
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Simvastatin, a HMG-CoA reductase inhibitor, have beenshown to exhibit 
important immunomodulatory effects independent of lipid lowering (Kwak Bet al., 
2000). simvastatin promote healing. By the following machanisms, 
 The basis of wound healing is the fact that statins increase the activity of eNOS& 
angiogenesis. There is a positive correlation between eNOS& 
angiogenesis;increase in which favors wound healing.Angiogenesis is required for 
restoration of blood flow for growing tissue.This is the basis of wound repair 
since it is essential for the supply of oxygen & other nutrients required in the 
cellular & biochemical process of the repair. 
 The other mechanisms involved in the pro-healing activity of statins include 
proper stimulation of the endothelial cell migration, proliferation & 
differentiation; since in vitro endothelial cell sprouting assays confirmed that 
eNOS is required for the same. 
 Inhibition of NAD(P)H oxidase leading to suppression of superoxide formation & 
oxygen free radical scavenging by statins could also help in promoting the healing 
by reducing oxidative damage. 
The objective of the present study was to develop Hydrogels loaded with 
simvastatin for the treatment of chronic wounds associated with diabetes melitus.  
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CHAPTER II 
A REVIEW ON NANOSTRUCRED LIPID CARRIERS 
A Novel Generation of Solid Lipid Carriers 
Many topical and dermatological formulations may susceptible to various changes 
if stored incorrectly. Emulsions may cream and crack,suspensions can agglomerate and 
cake, and ointments and gels may bleed as their matricescontract to squeeze out mobile 
constituents. High temperatures can produce or accelerate suchadjustments. Heat may 
alter the phasedistribution of cream and may even crack the emulsion. For milky white 
microemulsion creams or lotions it is difficult to determine ifthe final product requires 
additional mixing time to properly disperse or solubilize the drug. 
To overcome such problems of these multiphase systems, a new approach would 
be thepreparation of lipid nanoparticles for drug entrapment and furtherincorporation into 
a monophasic system such as hydrogels.  
Lipid nanoparticles were developed in the last decade of the last century as 
alternative carrier system to emulsions, liposomes and polymeric nanoparticles (Lucks 
and Müller, 1996; Mehnert and Mäder, 2001; Müller et al., 2000a,b, 1995). Drawbacks 
associated to the traditional colloidal systemsare the presence of solvent residues left over 
from production, the cytotoxicity of the polymers, and the lack of low-cost, qualified 
large-scale production units yielding a product of a quality acceptable by the regulatory 
authorities.  
In the majority of the pharmaceutical formulations intended for topical and 
dermatological therapy the drug molecules are totally dissolved in a liquid phase of oil-
in-water (o/w) or water-in-oil (w/o) emulsions.  A major disadvantage of emulsions and 
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liposomes is the lack of protection for chemically labile drugs, in addition drug release 
takes place as a burst (emulsions) or at least relatively fast (from liposomes) due to the 
low viscosity of the inner phase of the afore-mentioned systems.  
As an alternative, solid lipid nanoparticles (SLNs) were developed by exchanging 
the liquid lipid (oil) of the emulsions by a solid lipid (Muller R.H et al.,2000) matrix 
identical to polymeric nanoparticles(Siekmann Bet al., 1998) whichmay exhibit sustained 
releaseproperties. Another clear advantage of SLN compared to polymeric nanoparticles 
is the availability of large scale production units. However, there are also three 
limitations of the SLN system: limitation of drug load by the solubility of the drug in the 
solid lipid,drug expulsion phenomenon when lipid crystallizes to the stable β-form, 
particle concentration in the aqueous dispersions ranging from about 1% to a maximum 
of only 30%. The aim of the research was to overcome these limitations by creating a 
new lipid carrier, the NLC. 
Nanostructured lipid carriers (NLCs) are a second generation of SLNs, which 
have a solid matrix mixed with a liquid lipid (oil) to form an unstructured matrix that 
helps increase the drug loading capacity of nanoparticles, avoids or reduces drug 
expulsion from the matrix during storage and giving more flexibility for modulation of 
drug release.This approach is achieved by mixing solid lipids with liquid lipidsinstead of 
highly purified lipidsprferebly in a ratio of 70:30 upto a ratio of 99.9:0.1. The result is a 
less ordered lipid matrix with many imperfections, which can accommodate a 
higheramount of drug (Müller, R.H et al., 2004), (Müller, R.H et al., 2002).The overall 
solid content of NLC can be upto 95% (w/w) (Muller et all., 1999).(Müller, R.H et al., 
2002), (Müller, R.H et al., 2003). 
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TYPES OF NLC 
Imperfect type NLCs:In type I, solid lipids and liquid lipids (oils) are blended. 
The difference in the structures of the lipids and special requirements in the 
crystallization process lead to a highly disordered, imperfect lipid matrix structure 
offering space for drug molecules and amorphous clusters of drugs . 
Multiple type NLCs: When mixed with large amount of oil, the lipid was found to 
solubilize certain drugs which were not soluble otherwise. The multiple oil/fat/water, 
drug can be accommodated in the solid, but at increased solubility in the oily parts of the 
lipid matrix. At high oil concentrations a miscibility gap of the two lipids (solid lipid plus 
oil) occurs during the cooling phase, leading to phase separation that means precipitation 
of tiny oily nanocompartments. 
 
SLN NLC 
 
(Solid lipid blend) (Solid lipid + oil) 
 
 
Low oil                           High oilAmorphous 
 
 
drug 
 
 
 
 
 
 
 
I II III 
 
Amorphous NLC: It was created to reduce drug expulsion by mixing special lipids 
like hydroxyl octacosanylhydroxystearate and isopropyl myristate.In type III, lipids are 
mixed in a way that prevents them from crystallizing. The lipid matrix is solid, but in an 
amorphous state . The absence of crystallization avoids drug expulsion by crystallization. 
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Methods of preparation for  NLC 
High Pressure Homogenization 
High pressure homogenizers push a liquid with highpressure (100–2000 bar) 
through a narrow gap (in the range of a few microns). The fluidaccelerates on a very 
short distance to very high velocity (over 1000 km/h). 
Hot homogenization 
 
Cold homogenization 
Cold homogenization overcome various problems associated withhot 
homogenization such as temperatureinduced drug degradation, drug distribution into the 
aqueous phase during homogenization.In cold homogenization the drug containing lipid 
melt is cooled, the solid lipid ground to lipid microparticles and these lipid microparticles 
are dispersed in a cold surfactant solution yielding a presuspension. Then this pre-
suspension is homogenized at or below roomtemperature, the gravitation force is strong 
enough to break the lipid microparticlesdirectly to solid lipid nanoparticles. 
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Solvent emulsification-diffusion method 
The particles with average diameters of 30- 100 nm can be obtained by this 
technique. Voidance of heat during the preparation is the most important advantage of 
thistechnique 
Microemulsion based method 
 
 
Supercritical fluid 
NLC can be prepared by the rapid expansion of supercritical carbon dioxide 
solutions (RESS) method. Carbon dioxide (99.99%) was the good choice as a solvent for 
thismethod.7 
Spray drying method 
It's an alternative procedure to lyophilization in order to transform an aqueous 
NLC dispersion into a drug product. But his method can cause particle aggregation due to 
high temperature, shear forces and partial melting of the particle. 
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Double emulsion method 
In double emulsion technique the drug (mainly hydrophilic drugs) was dissolved 
inaqueous solution, and then was emulsified in melted lipid. This primary was stabilized 
by stabilizer. Then this stabilised primary emulsion was dispersed in aqueous phase 
containing hydrophilic emulsifier. Thereafter, the double emulsion was stirred and was 
isolated by filtration.  
Precipitation method 
The glycerides are dissolved in an organic solvent (e.g. chloroform) and the 
solution will be emulsified in an aqueous phase. After evaporation of the organic solvent 
the lipid will be precipitated forming  nanoparticles. 
Film-ultrasound dispersion 
The lipid and the drug were put into suitable organic solutions, after 
decompression, rotation and evaporation of the organic solutions, a lipid film is formed, 
then the aqueous solution which includesthe emulsions was added. Using the ultrasound 
with the probe to diffuser at last, the NLC with the little and uniform particle size is 
formed. 
Routes of Administration 
The research activities in SLN and NLC in the last two decades focussed mainly 
on pharmaceutical nondermaladministration routes, i.e. parenteral (Blasi et al., 2007; 
Joshi and Müller, 2009; Wissing et al., 2004), peroral (Muchow et al., 2008; Müller et al., 
2006; Sarmento et al., 2007), ocular (Attamaet al., 2007; Ugazio et al., 2002) and 
pulmonary (Liu et al., 2008) administration.  
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Advandages 
A clear advantage of the use of lipid particles as drug carrier systems is the fact 
that the matrix is composed of physiological components, i.e. excipients with generally 
recognized as safe (GRAS) status for oral and topical administration, which decreases the 
danger of acute and chronic toxicity.  It can also be pointed out that NLC are low cost 
products (Müller, R.H., 2005). In fact, the excipients and production lines are relatively 
cheap and the production costs are not muchhigher than those established for the 
production of parenteral emulsions (Wissing, S.A., 2004, Müller, R.H., 2004 ). 
Advantages of NLC as a Topical Drug Delivery system 
During the last 5 years SLN and NLC have been intensively investigated for 
dermal application because of many positive features that have been reported after their 
application to the skin (Müller et al., 2007, 2002b).  
Due to the lipid matrix, the small particle size and related adhesive properties, the 
residence time of NLC on the skin is prolonged. There is a lipid interaction of the particle 
matrix with skin surface lipids, affecting drug absorption (Lombardi Borgia et al., 2007; 
Santos Maia et al., 2002).  
Occlusive properties, increase in skin hydration, modified release of actives, 
targeting effects to specific skin strata especially when the drug is located at the particle 
surface are also positive features of lipid nanoparticles (Müller et al., 2007).  
NLC were found to enhance the skin penetration of several dermally applied 
drugs(Lombardi Borgia et al., 2005; Souto et al., 2004; Stecova et al.,2007). 
Concerning aqueous SLN andNLC dispersions, once composed of physiological 
lipids they might be less comedogenic thaneither creams or lotions. It will therefore be 
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possible to develop systems that are non-toxic,non-irritating, non-comedogenic and non-
sensitizing and formulating pharmaceutically and/orcosmetically elegant topical 
formulations based on NLC. 
Drug release profile from NLC based HG 
Drug penetration into certain layers of the skin can be achieved using NLC as a 
consequence of the creation of a supersaturated system (Müller, R.H et al., 2002). 
Lipid nanoparticles Supersaturated
(mean size 200 nm) drug solution
 
 
 
Application 
 
 
Lipid transition   βi / β   
Skin 
 
 
Semi-solid   
Water phase 
 vehicle Permeation pressure 
 
Lipid 
nanoparticles-
based semi-solid 
formulation 
 
Phenomenon of triggered drug release and supersaturation effect of lipid 
nanoparticles entrapped into a dermatological formulation, i.e. semi-solid vehicle 
(modified after Müller et al. (Müller, R.H., 2002). 
 
Incorporation of lipid nanoparticles such as NLC into topical formulations (gels) 
can be performed to create supersaturated systems to enhance the permeation of drugs 
across membranes such as skin without affecting  the ultrastructure of the stratum 
corneum.. The increase in saturation solubility will lead to an increased diffusion 
pressure of drug into the skin. 
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The developed semi-solid systems consist of a three-dimensional vehicle 
(hydrogel) which encloses and it is interpenetrated by an aqueous NLC dispersion. 
During storage, the drug remains in the lipid matrix because these particles preserve their 
modification. After application onto the skin, the increase in temperature and water loss 
observed lead to transformation to a more ordered lipid modification and are responsible 
for drug expulsion from the lipid matrix. The drug is expelled into the semi-solid vehicle 
(hydrogel ) already saturated with drug and thus leading to supersaturation. This 
phenomenon increases the thermoactivity and leads to drug penetration into the skin. 
Concerning the release properties of the developed formulations, the jellifying 
agent can modify the observed diffusivity of the drug from lipid nanoparticles by either 
mechanically impeding its movement or by adsorbing the drug on the polymer surface. 
Since the actual pathway for diffusion in gels is through the fluid phase, the factors which 
affect diffusivity in pure liquid phases similarly control diffusion within the gels. 
Polymeric systems such as hydrophilic gels, express non-Newtonian 
pseudoplasticbehaviour,. As the degree of pseudoplasticity increases, easiness of 
spreadability augments (das Neves et al., 2009). 
The scope of this studywas toformulation  ofsimvastatin loaded nanostructured 
lipid carrier and further incorporated into chitosan  hydrogel and to determine the effect 
of NLC based hydrogel of simvastatin on the extent of wound healing acceleration. To 
ascertain simvastatin’s wound healing acceleration superiority, simvastatin loaded NLC 
based HG will becompared with plain simvastatin HG and NLC based HG’s without 
drug. 
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CHAPTER III 
LITERATURE REVIEW 
 Prachi  B.Shekhawatet  al.,   2013, preparedClotrimazole  loaded  
Nanostructured  lipid  carrier  for  topical  delivery  by  hot  homogenization  
method using  Stearic  acid  as  solid  lipid,  oleic  acid  as  liquid  lipid.  
Combination  of  four  types  of  surfactants  : Tween 80,  Polaxamer  188,  
Sodium  Lauryl  Sulphate (SLS)  and  lecithin  were  used  to  stabilize  NLC  
dispersion.  The  penetration  of  Clotrimazole  from  CM-NLC  formulation  
into  cadaver  skin  was  evaluated  in vitro  using  franz  diffusion cell.  The  
CM-NLC  formulations  would  significantly  increase  the  accumulative  
uptake  of  CM  in  skin  over  the  marketed  gel  and  showed  a  significantly  
enhanced  skin  targeting  effect. 
 GajananShinde,et al., 2013, preparedMethoxalen loaded NLC by hot 
homogenization followed by High speed homogenization technique, using 
Glyceryldistearate, Compritol ATO 888 and Stearic acid as solid lipid, Ethyl 
oleate as liquid lipid and Pluronic F-68 as surfactant .The mean particle size, 
polydispersity index (PDI), zeta potential and entrapment efficiency were 
found to be 258.2 nm, 0.183, -20.9 mV, 97.45 %  respectively.  In vitro release 
studies demonstrated that NLC formulations possessed a controlled release 
over a period of 24 hrs. The pH, Viscosity, Spredability, Refractive Index, 
Drug content, Skin permeation, Drug deposition of prepared NLC based gel 
were characterised.NLC based gel was not shown skin irritation and shown 
prolong release up to 24 hr. There was insignificant change in pH, Drug 
content and In vitro release indicating the developed NLC were fairly stable.  
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 Gajanan S   Sanapet  al., 2013, designed  and  evaluated  Miconazole  
Nitrate  Loaded  Nanostructured Lipid  Carrier   for  improving  the  antifungal  
therapy.NLC  designed  for topical  application by  hot  high pressure   
homogenization  technique.  The lipid nanoparticles are incorporated in gels 
for convenient topical  application.  The  ln vitro  and  Ex vitro  skin  
permission   data  indicate  that  MN loaded  NLC  bearing  hydrogel  provides  
sustained  release  of MN. 
 Anne  des  Rieuxet  al.,  2013, studied  mechanism  of  transport  of  
Saquinavir loaded  Nanostructured Lipid  Carriers  across  the  intestinal  
barrier.  The  size  and  amount  of  surfactant  in  the  NLC  influenced  
SQV’s  permeability, transcytosis  pathway  efflux  of  SQV by  P-gp.  An  
NLC  of size 247 nm  and  1.5%  W/V  surfactant  circumvented  P-gp  efflux. 
 Sachin  S.Salunkheet  al .,     2013,    developed  Nanostructured  lipid  
carrier  for topical  delivery  of  Idebenone  by  using  solvent  precipitation  
method.Compriol  888  ATO,  Captex  500 P  and  ethanol  were  selected   as  
solid lipid, liquid  lipid  and  solvent  respectively.Labrasoland TranscutolP as 
surfactant and co-surfactant had  given  stable  formulations on the basis of 
HLB required for stabilization.  Animal  model  studies   such  as  in vitro  
skin  permeation,  skin  deposition,  sun  protection  factor  determination  
studies  gave  proof  for  effective  delivery  of  drug by incorporating   into  
NLC. 
 ShaimaaElkadiet  al.,   2013, designed  and  Optimized  the  self nano-
emulsifying  drug  delivery  systems  of  Simvastatin.  Oils,  surfactant and  
co-surfactant  composition  was  optimised  using drug  solubility,  tertiary  
phase  diagram,  system  stability  and  droplet  size  distribution 
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studies.Results revealed  that 10% relatively  polar  oils,  60%  Cremophore  
RH 40,  (surfactant)  and  30% Transcutol   HP  (co-surfactant)  acquired   
good  nano-emulsification  properties  either  in  liquid  or  tableted  forms. 
 Himeshsoniet al., 2013, formulated and optimized hydrogel systems 
containing rutin0.025% w/w which can improve the therapeutic efficacy of 
poor water soluble drugs. Hydrogels were prepared using Carbopol934 and 
HPMC in different concentrations of 2:1, 1:1, 1:2 along with methanolic 
dispersions of rutin. Hydrogel can sustain the release of rutin revealed that 
drug remains localized for a longer period of time, thus enabling drug 
targeting to the skin and feasibility of using a dermatological formulation to 
improve skin wound healing, inflammation and prevent microbial infection. 
 Almeida, Mariana Mandelliet al., 2013, prepared Nanostructured Lipid 
Carriers containing Ursolic acid in cosmetic formulation by High Pressure 
Homogenization  and evaluated physical and chemical stability of prepared 
NLC formulation by Accelerated Stability test under varying conditions of 
temperature and luminosity. Based on the results, the ursolic acid in the NLC 
form achieved a better physical and chemical stability compared to ursolic 
acid in the free form in both variation of the viscosity and pH. 
 GuissiNida El Islemet al., 2013, prepared and characterised low crystalline 
and more swollen Nimodipine loaded Nanostructured Lipid Carriers and Solid 
Lipid Nanoparticles in the presence of Electrolytes by modified solvent 
injection method using Glyceryl mono stearate as solid lipid, Soyabean oil as 
liquid lipid and Polaxamer 188 and tripolyphosphate as stabilizers. As a result, 
all developed formulations showed a narrow Polydispersity Index lower than 
0.3, good physical stability and Zeta potential value ranging from -34mV to -
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66mV approximately. SLN and NLCs prepared in the presence of Electrolytes 
have shown higher Entrapment efficiency (upto 87.52% ) , higher drug 
loading(4.19%) and increased drug release rate up to 96.7%. 
 Jun Asaiet al., 2012, done aresearch on “Topical Simvastatin shown to 
accelerate wound healing in diabetes”. Factors involved in delayed wound 
healing in diabetes include more rapid apoptosis, reduced angiogenesis and 
lymphangiogenesis.This study shows that topical Simvastatin significantly 
accelerates wound recovery by increasing both angiogenesis and 
lymphangiogenesis. The favourable effects of Simvastatin on 
lymphangiogenesis are due both to a direct influence on lymphatics and 
indirect effects via macrophages homing to the wound. 
 Michel    FleithOtukiet  al.,  2012,      prepared  Simvastatin  ointment  for  
the  treatment  of  skin  inflammatory  conditions.  The  aim  of  the  study  
was  to  investigate  the    activity  of  Simvastatin  in  acute  and  chronic  
inflammatory  models of mice. The  result  confirmed  the  anti-inflammatory  
activity  of  Simvastatin  when  applied  topically  in  both  acute  and  chronic  
models  of  skin  inflammation. Besides,  the  incorporation  of  1%  
Simvastatin  in  an  ointment  vehicle  maintained  its  anti-inflammatory  
activity  and  prevented  problems  associated  to  the  skin  barrier  disturption  
observed  with  a  preparation  of  a  higher  concentration ( 3% ).  
    
 Santhoshkumar R. Jeevangiet al., 2012, compared anti-inflammatory 
activity of Lovastatin, Simvastatin, Atorvastatin and Rosuvastatin on acute 
and chronic inflammation in animal models. All the statins showed significant 
anti-inflammatory activity in the present study in both acute as well as  
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chronic models of  inflammation. The anti-inflammatory activity of the 4 
statins was significant on comparision with Diclofenac. Lovastatin and 
Simvastatin demonstrated 10-20% more anti-inflammatory activity than 
Atorvastatin and Rosuvastatin. 
 Dilip Patel et al., 2012, done a research on Nanostructured Lipid Carriers  
based Gel for the topical delivery of Aceclofenac. Strearic Acid as the solid 
lipid, Oleic Acid as the liquid lipid, Pluronic F68 as the surfactantant and 
phospholipon 90G as the co-surfactant were used. NLCs were prepared by 
melt-emulsification, low-temperature solidification and high speed 
homogenization methods. The NLC dispersion was suitably gelled and 
assessed for invitro permeation. Finally NLC based gels were found to possess 
superior (almost double) the anti-inflammatory activity with rapid onset of 
action and prolonged duration of action compared to the marketed gel. 
 A.C. Silva  et  al.,  2012, developed  two  different  solid  lipid  Nanoparticles 
(SLN)  Loaded   hydrogel     as  potential  carrier  for  oral  transmucosal  
delivery  of Risperidone.  The  rheological  behaviour  of  semisolid  
formulations  revealed  a  plastic  flow  with  thixotrophy. The SLN remained 
within thecolloidal  range  after  the  preparation.  In vitro  release  studies  
revealed  a  more  pronounced  RISP  release  after  SLN  hydrogel  
entrapment  when   compared  to  the  dispersion  alone.  In addition  pH  
dependent  release  observed  as  well.  The  predicted  in vivo  RISP release  
mechanism  was  Fickian  diffusion  alone  (or) combined  with  erosion. 
 Evren it Gokceet al., 2012, compared Resveretrol loaded SLN versus  NLC.  
Nanoparticles  were  prepared  by  high  shear  homogenization  using  
Compritol   ATO (solid lipid), Miglyol (liquid lipid),  Polaxamer  188,  and  
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Tween  80.  NLC  formulation  containing  255 mg  of  Compritol  and  45 mg  
of  Miglyol  (15%  of  the  lipid  phase)  was  the  most  promising  
formulation.  The drug EE was 18%  higher  in  NLC  system.  Ex vivo  skin  
studies  revealed  that  NLC  are  more  sufficient in  carrying the RSV  to  the  
epidermis.  When  the  two  system  compared,  NLC  penetrated  deeper  into  
the  skin.   RSV  loaded  NLC  with  smaller  PS  and  higher  drug  loading    
appears  to  be  superior to SLN  for  dermal  applications. 
 SiripornOkonogiet al., 2012, carried out  a  project  on  effect  of surfactant  
on   Lycopene  loaded  Nanostructured lipid  carrier.  The preparation of the 
NLC was achieved by means  of  high  pressure  homogenization.  The result  
of  this  study  demonstrate  that  the  contact  angle  as  a  key  tool  to  
overcome  the  small  size  of  NLC . It was  found  that  small  contact  angle  
gave  NLC  with  small  size.  Plantacare  1200  gave  Lycopene  loaded  NLC  
with  smaller  size, high zeta  potential  and  narrower  size  distribution.        
 Sahu  M.K   et  al.,  2012, formulated  & characterized  the  topical  
Nanostructured  Lipid  carrier  gel  of Fluriprofen  and  its  comparison  with  
micellar  gel  preparation.  The Fluriprofenloaded  NLC  prepared  by  solvent  
diffusion  method.    The  encapsulation  efficiency  and  drug  loading  of  
Fluriprofen  loaded  NLC  was  in  the  range  of  78.28 - 72.13 %  and  21.84 - 
20.68 %  respectively.  The  particle  size  and  zeta  potential  of  prepared  
formulation  was  found  to  be  in  the  range  of  120.48 - 280.12 nm  and -
22.32 to -21.18  respectively.  FLUNLC showed  better  blood  concentration  
in vivo  (36.95 ± 1.23 µg.min/ml)  than marketed  fluriprofen  formulation 
(13.55 + 0.63) representing greater  plasma  level  of  fluriprofen  after 
administration.    
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 H.M.  Nguyen  et  al.,  2012, performed a  project  on  enhanced  payload   
and  photo-protection  for  pesticides  using  Nanostructured  lipid  carriers  
with  corn  oil  as  liquid  lipid.  Deltametherin  loaded  Nanostructured  lipid  
carrier  and  solid lipid nanoparticles  were  prepared   by  hot  homogenization  
and  sonication  with  different  ratios  of  corn  oil  (Liquid  lipid)  and  Bess  
wax  (solid  lipid ). Compared to solid lipid nanoparticles  (SLN),  NLC  gave   
a  higher  payload  (approximately  1.79  times)  with  high  encapsulation 
efficiency  (83.6%)  and  higher  photo protection in both direct photolysis (1.8 
times ) and in indirect photolysis (1.37 times ). 
 Premanand A.Nighojkaret al.,  2012, formulated  
BetaMethasoneDipropionateloaded  Nanostructured lipid  carrier  enriched  
gel  by  hot  homogenization  followed  by  ultrasonication  method.   BMP-
NLC enriched gel  using  Tyloxopol  as  surfactant andPhosphatidylcholine  as  
an  emulsifier  with  optimum  concentration  of  3.0%  and  2.0%  shows  least  
particle  size  (342.6nm),  high  entrapment  efficiency (85.50%) and  average  
drug  content  (0. 803 mg/ml).  Cumulative  percentage  of drug  release  of  
BMP-NLC  enriched  gels  showed  higher drug  permeation  (80. 5%)  
through  excised  rat  skin  at  the  end  of  24 hrs  and  stable  at  room  
temperature.  
 Huizhouet al.,  2012, encapsulated  Oxaliplatin  in  Nanostructured  lipid  
carriers  by  hot  high-pressure  homogenization  method.  Differential  
scanning  colorimetry  and  x-Ray  diffraction  studies  revealed  that  the  drug  
was  dissolved  in  the  blend  of  Glyceryl  mono stearate  and  medium  chain  
trigiylerides  with  amorphous  forms.  The  in  vitro  release  experiments  of  
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NLC  exhibited  biphasic  drug  release  pattern  with  burst  release  at  the  
initial  2 hr  and  prolonged  release  afterwards. 
 Samantha  C. Pinhoet  al.,  2012, developed  a lipid  particle  for  β-carotene  
using  blend of 70 % trisearin and  30 % sunflower oil (6 % total lipid )by hot 
pressure  homogenisation and stabilized  with  hydrogenated  soylecithin  and  
tween 80 (3% total surfactant).Two types of particles were produced, using 1 
and 2 passage in the homogenization step. The systems  in  terms  of  size  
distribution  although  the particles  produced with 1 passage were  slightly  
more  efficient  at  protecting the  beta-carotene  from  degradative  process  
and  also  suffered  less microstructural  alteration  after  4  months. 
 UsamaFarghalyAlyet al., 2012, prepared and evaluated Atorvastatin in 
different type of gels including hydroalcoholic, hydrogel, microemulsion, 
anhydrous and alcoholic gel bases. The prepared gels were evaluated for 
physical appearance, rheological behaviour, drug release through a standard 
cellophane membrane and wound healing power in Streptozotocin induced 
diabetic male albino rats. The rank order of gel formulations based on their 
maximum release was alcohol > hydrogel >hydroalcoholic> anhydrous 
>microemulsion gel base. Results of in vivo wound studies revealed that the 
anhydrous base showed the highest parent wound contraction with complete 
wound closure and epithelisation was observed on 7th day of wound 
contraction. 
 JaberEmamiet al., 2012, formulated Cholesterol Nanostructured Lipid 
Carriers (NLCs) with various Oleic Acid content loaded with Paclitaxel by 
solvent emulsification diffusion method using a Taguchi design. Size, Zeta 
Potential, Entrapment Efficiency, drug loading and release percent of NLC 
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were measured. The results indicated that most effective factor on size were 
Oleic Acid and Surfactant content. Zeta Potential was most affected by drug 
content. Drug to lipid weight ratio was the most effective factor on entrapment 
efficiency and drug release from NLC. 
 Dubey A.et al., 2012,reviewed nanostructured lipid carrier : A novel topical 
drug  delivery systems. This review concentrates on development of 
nanostructured lipid carrier for topical applications. The lipid nanoparticles 
SLN and NLC are carrier systems with good perspectives to be marketed very 
successfully. The reason is that they were developed considering industrial 
needs e.g. Scale up, qualification and validation, simple technology, low cost, 
tolerability etc. The smart NLC as the new generation offer much more 
flexibility in drug loading, modulation of release and improved performance in 
producing final dosage forms such as creams, tablets, capsules, and injectabes. 
 Sahuet al., 2012, reviewed Nanostructured Lipid Carrier : The second 
generation of solid lipid nanoparticles. SLN was referred to alternative carrier 
system to traditional colloidal systems such as liposomes, emulsions, and 
polymeric nanoparticles due to its exceptional stability, scaling up potential 
and bio-compatible components. A new generation of nanostructured lipid 
carrier consisting of a lipid matrix with a special nanostructure has developed 
with improved drug loading and storage. 
 Meghana S. Kambleet al., 2012, reviewed Solid lipid nanoparticles and 
nanostructured lipid carrier. To overcome the stability and drug expulsion 
problems  of SLN, The NLC had emerged. The highly unordered lipid matrix 
structure of NLC improved drug encapsulation and stability also presenting 
controlled and targeted drug release. NLC can be administered via oral, ocular, 
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pulmonary, and intravenous routes. The present reviews the types of NLC, 
preparation, methods, and characterization of SLN and NLC. 
 MahiranBasriet al., 2011,   done a project on “ an improved  method for the 
preparations of Nanostuctured lipid carriers containing heat sensitive 
boiactives”. A previously established high-temperature high-pressure 
homogenization technique involved in the preparation of the NLCs can cause 
degradation of heat sensitive active compounds during the preparation of 
NLC. In this work, modified methods A and B were developed on the basis of  
initial location of surfactants and fast cooling step after homogenization which 
enhance the chemical stability of heat sensitive compounds and physical 
stability of NLCs significantly compared to the previously established method. 
 CheeWun How et al., 2011, reviewed Physicochemical properties of 
nanostructured lipid carriers as colloidal carrier system stabilized with 
polysorbate 20 and polysorbate 80. NLC80 were produced by high-pressure 
homogenization technique, stabilized with polysorbate 20 and polysorbate 80, 
respectively. Photon correlation spectroscopy showed that the average size of 
NLC80 and NLC20 were 102.8 ± 0.1 and 261.63 ± 8.56 nm, respectively, and 
their zeta potentials were -23.93 ± 0.75 and -30.57 ± 0.06 mV, respectively. 
The results suggest that NLC80 is a more stable formulation. The melting 
point depression of NLC80 was 5.71°C below bulk lipid’s melting point 
(61.56°C), while NLC20 exhibited two melting points at 54.80 and 59.10°C. 
These findings suggest that polysorbate 80 was a better dispersing agent for 
NLC than polysorbate 20. The physicochemistry properties of the NLCs 
aregreatly influenced by the type of surfactant used. 
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 PardeikeJ. et al., 2011, developed an itraconazole loaded nanostructured lipid   
carrier formulation for pulmonary application. Selecting lipid matrix and 
stabilizers based on solubility and miscibility investigations and contact angle 
measurement respectively can help formulating NLC with good stability and 
high entrapment efficiency. Based on this Precirol and Oleic acid in the ratio 
of 9:1 as lipid matrix, 2.5% EumulginSLM 20 as stabilizer is used. An 
entrapment efficiency of 98.78% was achieved with Narrow size distribution 
and sufficient  stability.  
 Gambhire M.S et  al., 2011, formulated  Simvastatin  loaded  solid lipid  
Nanoparticles  by pre-emulsion ultra sonication  technique  and optimized  
using  Box. Behnken design.  The  results  of  optimized  formulation  showed 
average  particle  size  of  245 nm  and  drug   entrapment of 75.52%  
and  low in vitro  release  of  37.08%  than  dispersion  of pure  drug  (97.2%). 
 MakarandGrambhireet  al.,  2011,    studied  bioavailability  assessment  of  
Simvastatin  loaded solid  lipid  nanoparticles  after  oral  administration.  
Simvastatin SLN developed using  Compritol  888  ATO  by pre-emulsion  
followed  ultrasonication. Stable Simvastatin  SLN having  mean  size of  245 
nm  and %  entrapment  of  72.52%  were  formulated.  The  relative  
bioavailability  of  Simvastatin  and  Simvastatinhydroxy  acid  from  SLN 
were increased  by ~164%  and  ~207%  respectively  compared  with  
reference  Simvastatin  suspension. 
 LacerdaS.P. et al., 2011, prepared and characterised carnuba wax 
nanostructured lipid carrier containing benzophenone-3 by hot 
homogenization technique using carnuba wax as the solid lipid and 
isodecyloleate as liquid oil. The current investigation illustrates the effect of 
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the composition of the lipid mixture on the entrapment efficiency, in vitro 
release and stability of benzophenone-3 loaded in these NLCs. A loading 
capacity of approximately 5% of BZ-3 (µgBZ-3/mglipids) was characteristic of 
these systems. 
 Varsha B. Pokharkaret al., 2011, developed and optimized Eugenol loaded 
nanostructured lipid carriers for periodontal delivery by hot homogenization 
method. High entrapment efficiency was attributed to the imperfections in the 
crystal lattice leading to increased drug loading. NLC based gel exhibited 
initial faster onset of release followed by sustained release as evident from 
comparative study of plain with drug loaded gel.NLC based gel were found to 
be stable for six months as per ICH guidelines. 
 Yamsani MR et al ., 2011, formulated Domberidone loaded solid lipid 
nanoparticles and nanostructured lipid carrier by hot homogenization followed 
by ultrasonication technique using Trimyristin as solid lipid, CetylPalmitate as 
liquid lipid and a mixture of soyphosphatidylcholine (99%) and Tween 80 as 
surfactant. The entrapment efficiency and the drug release profile depend on 
the concentration of lipid and surfactant mixture employed. NLC showed 
higher entrapment efficiency and faster release profile compared to SLN. 
 Hyun jin Park et al., 2010, reviewed anti-microbial properties of chitosan and 
mode of action. Owing to its high biodegradability, non-toxicity and 
antimicrobial properties,Chitosan-mediated inhibition is affected by several 
factors can be classified into four types as intrinsic, environmental, 
microorganism and physical state according to their respective roles. In this 
review antimicrobial activity in soluble state and solid state are comparatively 
discussed.  
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 Yin-ku Lin et al., 2010, evaluated the potential of nanostructured lipid carrier 
(NLCs) loaded with lipophilic Calcipotriol and hydrophilic Methotrexate as 
topical therapy. NLC composed of Precirol ATO 5 with various amount of 
squalene as the liquid lipid were prepared. The range of particle size of the 
NLC preparations was 270 to 320 nm, with vehicles containing a higher 
Precirol amount exhibiting a larger diameter. NLCs with a higher 
Precirol/Squalene ratio also showed greater polarity in their molecular 
environment. The present work confirmed that NLC systems are a promising 
carrier for the topical delivery of anti-psoriatic drugs as revealed by enhanced 
skin permission, negligible skin irritation and the compatibility of the two 
drugs. 
 Rania A. Sanadet al., 2010, formulated Oxybenzone loaded Nanostructured 
Lipid Carriers (NLCs) by solvent diffusion method and evaluated using a 
complete 23 factorial design. The study design involves the investigation of the 
effect of three independent variables namely liquid lipid type (Miglyol 812, 
Oleic acid), liquid lipid concentration (15% and 30% ) and Oxybenzone 
concentration (5% and 10% ) on particle size and entrapment efficiency. NLCs 
prepared using Miglyol 812, 15% liquid type, 10% Oxybenzone showed lower 
particle size, higher %EE and slower drug release when compared to those 
prepared using Oleic acid. The incorporation of Oxybenzone into NLC greatly 
increased the sun protection factor, erythemal UVA protection factor with the 
advantage of overcoming the side effects of free Oxybenzone as evidenced by 
low irritation potential. 
 Ibrahim A. Alsarraet al., 2009, formulated Chitosan topical gel in the 
management of burn wounds. The treated wounds were found to be contract at 
Chapter III  Literature Review 
 
NLC Based HG for Diabetic wound healing,Reg.No:261211309  Page 37 
 
the highest rate with high molecular weight-high degree of acetylation 
Chitosan treated rats as compared to untreated and fusidin ointment treated 
rats. Histological  examination and collagenase actively studies revealed 
advanced granulation tissue formation and epithelisation in wounds treated 
with high molecular weight Chitosan than medium or low molecular weight 
Chitosan. 
 KesavanBhaskar et al., 2009,  prepared aqueous dispersions of lipid 
nanoparticles – Fluriprofen solid lipid nanoparticles and 
fluriprofennanostuctured lipid carriers by hot homogenization followed by 
sonication  technique and then incorporated into freshly prepared hydrogels 
for transdermal delivery. FLUNLC showed higher entrapment efficiency and 
faster release profile in comparison to FLUSLN. Both SLN and NLC 
dispersions and gels enriched with SLN and NLC possessed   a sustained drug 
release over a period of 24 hour but the sustained effect was more pronounced 
with the SLN and NLC gel formulations. The pharmacokinetic parameter 
obtained with transdermal gels indicate that the prolonged elimination half and 
increased bioavailability of the drug from gels compared with oral 
administration. 
 Jei Lai et al., 2009, investigated Glyceryl mono oleate (GMO) / Polaxamer 
407 cubic nanoparticles as potential oral drug delivery system to enhance the 
bioavailability of the water insoluble model drug Simvastatin. Almost 
complete entrapment with efficiency over 98% was achieved due to the high 
affinity of Simvastatin to the hydrophobic regions of the cubic phase. 
Pharmacokinetic profiles in beagle dogs showed sustained plasma levels of 
Simvastatin for cubic nanoparticles over 12 hour. 
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 VandanaPatravaleet al., 2008, designed and   evaluated  Nanostructured 
Lipid  Carriers for  parenteral delivery of artemether (ARM).  Nanoject NLC 
of ARM were formulated by micro emulsion template technique.  NLC of 
ARM offer significant improvement  in  the  anti-malarial  activity  and  
duration  of  action  of  ARM  as  compared  to  the  conventional  injectable  
formulation.   
 Amdiacinthia menses do regoet al., 2007, studied “Simvastatin improves the 
healing of infected skin wounds of rats”. A bacteriological exam of wounds 
fluid for gram positive and gram negative bacteria, the tecidual expression of 
TNF-α and IL-1α by immune histochemical technique and histological 
analysis by HE stain in a group is performed whose open infected skin wounds 
were treated with topical application of Simvastatinmicroemulsion and a 
second group wounds treated with saline 0.9%. In comparision, wound tissue 
from SIM group displayed less leucocyte infiltration and revealed wound 
infection in only one rat of SIM group, whereas polynominal infection is 
detected in saline group.   
 Silva.A.C et al., 2007, devoloped Nanostructured Lipid Carriers based 
hydrogel formulation for topical delivery of Minoxidil for the treatment of 
alopecia.Lipid nanoparticles are devoloped using stearic acid as solid lipid, 
Oleic acid as liquid lipid Polaxamer as Surfactant and the formulation was 
investigated as drug delivery systems by incorporating into hydrogels by using 
water soluble polymers.Thedeveloped NLC- based hydrogel formulation was 
shown to be a promising alternative to the conventional solution of minoxidil, 
avoiding the risk of undesirable side effects with increased therapeutic 
efficiency. 
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 SoutoE.B. et al., 2006,carried out a project on “The use of SLN and NLC as 
topical particulate carriers for imidazole anti-fungal agents”. In aqueous NLC 
dispersions prepared with Tripalmitin and Miglyol approximately 95% of 
clotrimazole was recovered after one year at room temperature. In the system 
developed for ketoconazole delivery only 54% of drug was recovered after 
one year at same temperature. These results emphasise the effect of the nature 
of the lipid as well as of the drug in chemical stability of system. Samples 
stored at 4ºc and particularly NLC-Based formulations showed to be more 
suitable for topical purpose. 
 Uner M.et al., 2005, studied skin moisturizing effect and skin penetration of 
AscorbylPalmitate entrapped in Solid Lipid Nanoparticles (SLN) and 
Nanostuctured Lipid Carrier (NLC) incorporated into hydrogel.SLN and NLC 
were found to sustain the penetration of AP through excised human skin about 
½ and 2/3 times compared to NE ( P<.001 and P<0.01 ), respectively due to 
the solid state of Witepsol E85 in the lipid phase. 
 Sun Hang choet al., 2004, developed  selfmicroemulsifying drug delivery 
systems (SMEDDS) for oral bioavailability enhancement of Simvastatin in 
beagle dogs. The optimal formulation of SMEDDS containing Simvastatin 
(high drug loading and small particle size) was as follows :Capryol 90 of 37%, 
Carbitol of 28% and Cremaphore EL of 28% as oil, surfactant and co-
surfactant respectively. In vitro dissolution studies and in vivo studies revealed 
that significantly greater drug release and higher extend of absorption  than the 
conventional tablet. 
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CHAPTER IV 
AIM OF THE WORK 
Chronic wounds develop from slow healing tissue injuries (beyond 12 weeks) 
which often reoccur. The reasons of healing failure depend on repeated tissue insults 
or underlying physiological conditions such as diabetes and malignancies, persistent 
infections, poor primary treatment and other patient related factors. Diabetes mellitus 
is one of the metabolic disorder that implies normal steps of wound healing process. 
Simvastatin belongs to the most effective class of drugs which lowers plasma 
cholesterol levels by competitive inhibitionof the HMG-CoA reductase, responsible 
for the first step in the synthesis of sterols. Clinical studies provide growing evidence 
thatstatins have been shown to have a number of beneficial effects that are not related 
to lipid lowering. Statins have anticoagulant, immunosuppressive, and 
antiproliferative effects that could conceivably affect wound healing or the risk of 
wound complications by increasing both angiogenesis and lymphangiogenesis. 
Moreover, the safety profile of statins is excellent and the major side effects are rare 
and mostly reversible. 
Topical drug delivery with conventional dosageforms like creams, ointments 
and moisturizers offer disadvantages viz. difficulty to control and regulate the 
amount of drug reaching the differentlayers of skin, this problem can be overcome by 
formulating the drug using acarrier that can enhance the permeation efficiency, 
increase contact time andare easy and stable upon formulation.Nanostructured Lipid 
Carriers (NLC) are one of the promisingformulations that can be used for topical 
delivery of drug; they are used as analternative to liposomes and emulsions as drug 
delivery system. NLC offeradvantages like, controlled release, drug targeting, 
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penetration enhancementand increased skin hydration, NLC’s can also overcome the 
problemassociated with solid lipid nanoparticles. As they have high loading 
capacityand there is reduced chances of drug expulsion during storage. Moreoverlarge 
water content associated with solid lipid nanoparticles creates apotential problem of 
incorporating them as topical formulations. Since NLCare small particles with size 
less than 400nm, their ability to cause skinhydration due to occlusion of skin is more, 
that increases the stratum corneumhydration and thus improves the percutaneous 
absorption of drug.  
The main objective of the project was the development of topical formulation 
to be applied in treatment of skin wounds. Hydrogels are one of the most popular 
types of wound dressings, have shown thesuperiority as they can provide a moist 
environment for the wound and at the sametime deliver the incorporated drug to the 
woundand hydrogels of natural origin are known to have several advantages( high 
biodegradability non-toxicity and anti-microbial properties) over synthetic origin 
hydrogels, Chitosan based hydrogels were selected as delivery system for wound 
treatment. 
The objective of the present study was to develop formulations of NLC based 
hydrogel for topical delivery of Simvastatin. The prepared gels were evaluated for 
physical appearance, texure analysis, skin sensitivity test, ex-vivo permeation study, 
drug deposition study and wound-healing power in allaxon-induced diabetic male 
albino rats. 
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CHAPTER V   
PLAN OF WORK 
A) STANDARD CURVES FOR SIMVASTATIN: 
1. Preparation of  calibration medium. 
2. Estimation of (absorption maximum) λmax . 
3. Preparation of calibration  curve using saline phosphate  buffer solution 
pH(7.4) containing 0.15% SDS. 
B) COMPATIBILITY STUDIES FOR DRUG AND LIPID: 
1. Infrared (IR) spectroscopic studies.  
2. Differential scanning Colorimetric (DSC) studies.                                                                       
C) FORMULATION OF SIMVASTATIN LOADED NANOSTRUCTURED  
LIPIDCARRIER: 
Formulation of simvastatin loaded nanostructured lipid carrier using different 
lipids (glycerylmonostearate, glyceryl monooleate,  glycerylbehenate, propylene 
glycol mono caprylate, stearic acid and oleic acid) at   different drug to lipid ratios  
(1:3, 1:5 and 1:7) and   different  stabilizers(Phopolipon 90G) concentration (1%, 2% 
and 3%) by using hot homogenizationtechnique followed by ultrasonication. 
D) CHARACTERIZATION OF SIMVASTATIN LOADED 
NANOSTRUCTURED LIPID CARRIER (NLC): 
1. Determination of physical properties. 
2. Determination of drug content. 
3. Determination of drug entrapment efficiency by centrifugation method. 
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4. In vitro release studies of Simvastatin loaded nanostructured lipid carrier using 
dialysis membrane. 
5. Kinetics of drug release 
6. Determination of particle size and zeta potential using Malvern particle size 
analyser 
7. Selection and evaluation of best formulation. 
a. Infrared (IR) Spectroscopic studies. 
b. Morphology of NLC by Scanning electron microscopy (SEM) 
technique.  
E)  SIMVASTATIN LOADED NLC BASEDHYDROGEL 
 Hydrogels(HG) are prepared using Chitosan-4%, followed by the drug & the 
selected best NLC formulations were incorporated into the HG in order to obtain plain 
& NLC based hydrogels respectively. 
F) EVALUATION OF  PREPARED NLC BASED HYDROGEL 
1. Determination of Physicochemical properties 
2. pH Measurements 
3. Drug Content 
4. Texture analysis 
5. Ex vivo skin permeation studies 
6. Drug deposition study 
7. Ex-vivo Release Kinetics 
8. Invivo Diabetic wound healing activity 
9. Skin sensitivity Test 
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CHAPTER VI 
MATERIALS & EQUIPMENTS 
MATERIALS USED: 
S.NO MATERIALS DISTRIBUTORS 
1 Simvastatin 
Gift sample from Bafna Pharmaceuticals,
Chennai. 
2 Glyceryl mono stearate Central drug house, New Delhi. 
3 Glyceryl behenate Orchid Pharma, Chennai. 
4 Stearic acid Central Drug House (P) Ltd, New Delhi 
5 Glyceryl mono oleate Otto chemicals, Mumbai. 
6 
Propylene glycol mono 
caprylate 
Gift Samples from Gattefosse India Pvt 
Ltd, Mumbai  
7 Oleaic acid Central Drug House (P) Ltd, New Delhi 
8 Phospolipon 90G 
Gift sample from phospholipid GmbH, 
Germany 
9 Tween 80 Lobachemie, India 
10 Chitosan Himedia Lab, Mumbai 
11 
Disodium hydrogen 
phosphate 
Nice chemicals Pvt Ltd, Kerala. 
12 
Potassium dihydrogen 
phosphate 
High purity laboratory chemicals, 
Mumbai. 
13 Sodium chloride Central Drug House (P) Ltd, New Delhi. 
14 Sodium Dodecyl Sulphate Rankem Laboratory Reagent, New Delhi 
15 Acetonitrile Central Drug House (P) Ltd, New Delhi 
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EQUIPMENTS USED: 
S.NO EQUIPMENTS SUPPLIERS 
1 Electronic weighing balance A & D Company, Japan. 
2 UV-Visible spectrophotometer Shimadzu Corporation, Japan. 
3 FT-IR Shimadzu, Japan. 
4 Texture Anayser TA- XT Plus  Stable Microsystems, UK 
5 
Differential Scanning 
Calorimetry 
DSC Q 200, Mumbai. 
6 Mechanical stirrer Scientific industries, India. 
7 Magnetic Stirrer MC Dalal & co, Chennai. 
8 Cooling Centrifuge Apparatus 
Eppendorf Centrifuge 5417R, 
Germany 
9 Scanning electron microscope Hitachi X650, Tokyo, Japan 
10 Particle size analyser Malvern Instrument, U.K. 
11 Environmental chamber Inlab equipments Pvt. Ltd, Madras. 
12 Rotary shaker Secor, India. 
13 Refrigerator Kelvinator, India. 
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CHAPTER VII 
DRUG PROFILE 
SIMVASTATIN  
STRUCTURAL FORMULA 
 
SYNONYMS 
SYNVINOLIN 
VELASTATIN 
L-644128-000U 
MK 733 
EMPIRICAL FORMULA 
C25 H38 O5 
CHEMICAL NAME 
(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl]- 
3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl,2,2-dimethylbutanoate 
Chapter VII  Drug Profile 
 
NLC Based HG for Diabetic wound healing,Reg.No:261211309  Page 47 
 
DESCRIPTION 
Nature     : White crystalline powder 
Molecular weight    : 418.6 
Solubility : Practically insoluble in water; Freely soluble in 
alcohol,   chloroform and in methanol 
partition coefficient (octanol/water)   :4.68 
MECHANISM OF ACTION 
 Simvastatin, a cholesterol- lowering agent derived from fungi Aspergillusterreus. 
When given orally, simvastatin (a lactone) undergoes hydrolysis and is converted to the 
β-hydroxyacid form by cytochrome-3A, a potent competitive inhibitor of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG CoA) reductase; the enzyme which catalyses the 
conversion of HMG-CoA to mevalonate, which was an early and rate limiting step in the 
biosynthesis of cholesterol. The competitive inhibition of the enzyme HMG-CoA 
reductase promotes two physiological responses in addition to the reduction in plasma 
cholesterol, increase in the number of low density lipoprotein (LDL) hepatic receptors 
and immunomodulatory activities. Clinical studies provide growing evidence that statins 
present anti-inflammatory properties including a reduction of inflammatory mediators 
such as C-reactive protein, interleukin-6 ( IL-6), tumour necrosis factor-a (TNF-a), 
monocyte chemoattractant protein-1 (MCP-1) and the endothelium-leukocyte interaction. 
 Simvastatin increases the bioavailability of nitric oxide upregulating NOS and by 
increasing the stability of NOS through post-transcriptional polyadenylation. It is unclear 
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as to how Simvastatin brings about these effects though they may be due to decreased 
concentrations of mevalonic acid. 
PHARMACOKINETICS 
 Absorption:Peak plasma concentrations of active plus latent inhibitors (total 
inhibitors) of simvastatin were attained within 1.3 to 2.4 hours postdose.  While the 
recommended therapeutic dose range is 5 to 40 mg/day, there was no substantial 
deviation from linearity of AUC of inhibitors in the general circulation with an increase 
in dose to as high as 120 mg. Relative to the fasting state, the plasma profile of inhibitors 
was not affected when simvastatin was administered immediately before an American 
Heart Association recommended low-fat meal. The absolute bioavailability of β-
hydroxyacid is 5%. 
 Distribution:  Both simvastatin and it’s β-hydroxyacid metabolite are about 98% 
and 94%  bound to plasma proteins respectively. 
 Metabolism: Simvastatin is administered as an inactive lactone prodrug and has 
two separate metabolic pathways. Oxidative biotransformation is the primary pathway 
mediated primarily by cytochrome P450 isoenzyme CYP3A4, and hydrolyzation of 
simvastatin acid by carboxylesterase is another pathway leading to non-enzymatic 
metabolism into an active β-hydroxyacid form. The major active metabolites include 3-
hydroxy, 3-hydroxy-3-methyl and 3-oxomethylene derivatives and its analogues of 6-
hydroxymethyl and 6-carboxylic acid derivatives (these are the biliary metabolites). 
Chapter VII  Drug Profile 
 
NLC Based HG for Diabetic wound healing,Reg.No:261211309  Page 49 
 
Excretion: The drug and its metabolites are primarily excreted in the feces (90%) 
and about 10 to 15% is recovered in the urine, mainly in inactive forms. The half life of 
the active β-hydroxyacid metabolite is 1.9 hours and simvastatin is 2 hours. 
 Age: There were no difference in plasma concentrations of simvastatin between 
elderly and younger patients. 
INDICATIONS AND USAGE 
 Used as an adjunt to dietary therapy to treat primary hypercholesterolemia 
(heterozygous familial and nonfamilial) mixed dyslipidemia and hypertriglyceridemia 
and used to reduce the risk of CHD mortality and cardiovascular events. Also indicated 
for homozygous familial hypercholesterolemia as an adjunct to other lipid lowering 
therapies or when other such therapies are not available. 
DOSE 
 5-80 mg orally once daily 
DOSAGE FORMS 
Tablet-Oral 5mg, 10mg, 20mg, 40mg, 80mg 
ADVERSE EFFECTS  
Rhabdomyolysis with myoglobinuria and acute renal failure and myopathy 
(including myolysis). 
Upper respiratory infection 
Headache 
Myalgia 
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Abdominal pain 
Constipation and Nausea 
OVERDOSE 
There is no specific treatment in the event of overdose. In the event of overdose, 
thepatient should be treated symptomatically and supportive measures instituted as 
required. Hemodialysis does not significantly enhance clearance ofclearance of 
simvastatin (Drug Bank: Simvastatin). 
WARNINGS AND PRECAUTIONS 
Skeletal muscle effects (e.g., myopathy and rhabdomyolysis) 
Risks increase with highest doses and concomitant use of certain medicines like 
cyclosporine and Danazol. Predisposing factors include advanced age (≥ 65) , female 
gender, uncontrolled hypothyroidism and renal impairment. 
Patients should be advised to promptly report any unexplained and/or persistent  
muscle pain, tenderness, or weakness. Simvastatin theraphy should be discontinued 
immediately if myopathy is diagnosed or suspected. 
Liver enzymes abnormatilies and monitoring 
 Persistant elevations in hepatic transaminases can occur. Monitor liver enzymes 
before and during treatment. (www.fdadrug.info.cfm). 
Persistant elevations in hepatic transaminases can occur. Monitor liver enzymes 
before and during treatment.(www.fdaDrug.Info.cfm) 
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          Solvent solubility : soluble in methanol and chloroform mixture 
          HLB value  : 5.0 
 Molecular weight : 358.56 
Functional category : Emulsifying agent 
STABILITY AND STORAGE CONDITIONS: 
It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from  light. 
SAFETY: 
It is generally regarded as an essentially non-toxic and non-irritant material at the 
levels employed as an excipients. 
HANDLING PRECAUTIONS: 
Keep away from heat and  ignition.  
REGULATORY STATUS : 
Induced in the FDA inactive ingredients.Recognized by GRAS status.(Handbook 
of Pharmaceuticals Excipients., 2009, 831-824) 
 
STEARIC ACID 
SYNONYMS: 
Cetylacetic acid; stereophonic acid; Tegostearic. 
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STRUCTURE: 
CHEMICAL NAME: 
Octadecanoic acid  
EMPIRICAL FORMULA: 
          C18H36O2 
DESCRIPTION: 
          Physical state          :     Crystalline solid/white or yellowish powder. 
          Melting point          :          554°C 
          Boiling point           :         383°C 
          Solubility                :          Freely soluble in benzene, carbon tetrachloride, 
chloroform, and ether; soluble in ethanol (95%), hexane, 
and propylene glycol; practically insoluble in water. 
 HLB value            :          15 
Molecular weight: 284.47 
Functional category :   Emulsifying agent ,Solubilizing agen,  Tablet and 
capsule lubricant 
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STABILITY AND STORAGE CONDITIONS: 
          It is a stable material; an antioxidant may also be added to it. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
SAFETY  
          It is generally regarded as a nontoxic and nonirritant material. However, 
consumption of Excessive amounts may be harmful. 
HANDLING PRECAUTIONS  
          Stearic acid dust may be irritant to the skin, eyes, and mucous membranes. Eye 
protection, gloves, and a dust respirator are recommended. Stearic acid is combustible. 
REGULATORY STATUS  
          Included in the FDA Inactive Ingredients Guide (sublingual tablets; oral capsules,  
solutions, suspensions, and tablets; topical and vaginal preparations).  
 
GLYCERYL BEHENATE 
SYNONYMS: 
Compritol 888 ATO; 2,3-dihydroxypropyl docosanoate; docosanoic acid, 
glycerylmonobehenate, 1,2,3-Propanetriol docosanoate. 
STRUCTURE: 
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EMPIRICAL FORMULA: 
C3H8O3.x(C22H44O2) 
DESCRIPTION: 
Physical state          :    Fine white powder 
Melting point          :    65–77ºC 
Boiling point           :     306 ºC 
Solubility                 :  Soluble, when heated, in chloroform and dichloromethane, 
practically insoluble in ethanol (95%), hexane, mineral oil,  
HLB value               :         12 
Molecular weight : 414.66 
Functional category : Coating agent, Tablet binder, Tablet and capsule lubricant 
STABILITY AND STORAGE CONDITIONS: 
It should be stored in a tight container, at a temperature less than 358C. 
SAFETY: 
It is generally regarded as a relatively nonirritant and nontoxic material. 
HANDLING PRECAUTIONS: 
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It emits acrid smoke and irritating fumes when heated to decomposition. 
REGULATORY STATUS : 
Included in the FDA Inactive Ingredients Guide (capsules and 
tablets).(www.sciencelab.com, www.parchem.com, Handbook of Pharmaceuticals 
Excipients., 2009, 819-824.) 
 
PROPYLENE GLYCOL MONOCAPRYLATE 
SYNONYMS: 
Capryol 90, 1,2propanediolmonocaprylate, Propylene glycol caprylate 
EMPIRICAL FORMULA: 
C11 H22 O3 
STRUCTURAL FORMULA: 
 
DESCRIPTION: 
Appearance  : oily liquid 
Odour  : Faint 
HLB VALUE : 6 
Molecular weight : 202.29 
 
STORAGE 
Stable under ordinary condition. 
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APPLICATION 
It is used as a lipophilic emulsifier and emulsion stabilizer in food and personal care 
products.(www.chemicalland 21.com) 
 
OLEIC ACID 
SYNONYM 
 Crodolene, Crossential 094, elaic acid glycon, Oeic acid, Priolene. 
CHEMICAL NAME 
 (Z)- 9- octadecenoic acid. 
EMPIRICAL FORMULA 
 C18 H34 O2 
DESCRIPTION 
 A yellowish to pale brown oily liquid with characteristic of lard like odour
 Boiling point   : 286oC 
 Density  : 0.895 g/Cm3 
 Melting Point            : 4oC 
Solubility  : Miscible with benzene, chloroform,ethanol(95%), 
ether, hexane, and  fixed and volatile oils, practically insoluble  in water 
Molecular weight  :   282.47 
FUNCTIONAL CATEGORY 
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 Used as an emulsifying agent in foods and topical pharmaceutical formulations. 
 To improve the bioavailability of poorly water-soluble drugs. 
 It is used in oral and topical pharmaceutical formulations as a penetration enhancer.  
STABILITY 
 An exposure to air, gradually absorbs oxygen, darkens in colour, and develops a 
more pronounced odour. At atmospheric pressure, it decomposes when heated at 80-
100oC 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
LD50 (rat oral) - 74g/Kg. 
HANDLING PRECAUTIONS 
Eye protection and Gloves are recommended. 
REGULATORY STATUS 
 GRAS listed. 
 
 
GLYCERYL MONOOLEATE 
SYNONYM 
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 It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from light. 
SAFETY 
 It is generally regarded as an essentially non-toxic and non-irritant material at the 
levels employed as an excipients. 
HANDLING PRECAUTIONS 
Keep away from heat and  sources of ignition. Empty containers pose a fire risk, 
evaporate the residue under a fume hood. Ground all equipment containing material. Do 
not breathe dust. (www.sciencelab.com, www.parchem.com,) 
 
PHOSPHATIDYLCHOLINE (PHOSPHOLIPON 90) 
CHEMICAL NAME [69] 
[(2R)-3-hexadecanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-
(trimethylazaniumyl)ethyl phosphat   
EMPIRICAL FORMULA 
 C42H82NO8P 
DESCRIPTION 
 Pale yellow to yellow granular powder 
Moisture  :  maximum 1.5% 
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Acid value  :  maximum 0.5 
Peroxide value :  0.5  
Molecular weight : 790 
Functional category : Solubilizer,Emulsifier, Micelle forming agent 
STORAGE 
Under dry condition, at maximum 8oC sealed under inert gas.Stored in a freezer at 
-20oC further improves the shelf life and is therefore recommendable. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
APPLICATIONS 
Preparation of mixed micelles, liposomes and microemulsions. 
Solubilizer for parenteral administration forms 
Emulsifier for pharmacy, dermatology and cosmetics 
 
POLYSORBATE 80 
SYNONYM 
Atlas E, Cappmul POE-O, Glycospere o-20,Tego SMO 80,Tego SMO 80 X, Tween 80. 
STRUCTURE 
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Emulsifying agent.Nonionic surfactant, Solubilizing agent, Wetting agent 
STABILITY 
Gradual soap formation occurs with strong acids or bases 
Stable in weak acids or bases. 
STORAGE 
It should be stored in a well-closed container in a cool, dry place. 
SAFETY 
Daily intake according to the WHO limit is about 25mg/Kg body weight LD50 
(Mouse, oral)-25g/Kg. 
HANDLING PRECAUTIONS: 
Eye protection and Gloves are recommended. (Handbook of Pharmaceuticals 
Excipients., 2009) 
 
CHITOSAN 
Chitosan is the term applied to deacetylated chitins in various stages of 
deacetylation and depolarization and it is therefore not easily defined in terms of its exact 
chemical composition. Partial deacetylation of chitin results in the production of chitosan 
which is a polysaccharide comprising copolymers of glucosamine and n-
acetylglucosamine.Chitosan is commercially available in several types and grades that 
vary in molecular weight between 10,000 and 1,000,000 and vary in degree of acetylation 
and viscosity. 
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SYNONYMS  
2-amino-2 –deoxy-(1,4)-ß-d-glucopyranan; deacetylated chitin; deacetyl chitin; ß-
1,4- amino 2-deoxy-d-glucopyranosamine 
CHEMICAL NAME 
 poly-ß-(1,4)-2-amino-2-deoxy-d-glucose 
DESCRIPTION 
chitosan occurs as odorless,white or creamy whitepowder or flakes.fibre formation 
is quite common during precipitation and the chitosan may look ‘cotton like’. 
STRUCTURAL FORMULA 
 
FUNCTIONAL CATEGORY 
Coating agent, disintegrant; film forming agent; mucoadhesive; tablet binder; 
viscosity-increasing agent 
 
TYPICAL PROPERTIES: 
Acidity 
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pH 4.0-6.0(1%w/v aqeous solution) 
Density-1.35-1.40 g/cm3 
Glass transition temperature-203oC 
SOLUBILITY 
Sparingly soluble in water, practically, insoluble in ethanol95% and other organic 
solvents and neutral or alkali solutions at pH above 6.5. 
INCOMPATIBILITY 
Chitosan is incompatible with strong oxidizing agents. 
SAFETY  
Chitosan is investigated widely for use as an excipient in oral and other 
pharmaceutical formulation. It is biocompatible with both healthy and infected 
skin.chitosan has been shown to be biodegradable. 
STABILITY AND STORAGE CONDITIONS: 
Chitosan powder is a stable material at room temperature, although it is 
hygroscopic after drying. Chitosan should be stored in tightly closed comtainer in a cool, 
dry place and it should be stored at a temperature of 2-80c 
 
CHAPTER – IX 
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CHAPTER IX 
EXPERIMENTAL PROTOCOL 
A) STANDARD CURVES FOR SIMVASTATIN 
1. Preparation of calibration medium: (U.SPharmacopoeia ., 2007) 
 Phosphate buffer saline (PBS) pH 7.4containing 0.15% sodium dodecyl 
sulfateis prepared by dissolving 1.5 g of sodium dodecyl sulfate,2.38g of disodium 
hydrogen phosphate, 0.19 g of potassium dihydrogen phosphate and 8 g of sodium 
chloride in 1000 ml of distilled water. The pHis adjusted if necessary. 
2. Determination of (absorption maximum) λmax: 
A stock solution is prepared by dissolving an approximate quantity (100 mg) 
of pure drug in 100 ml Acetonitrile (1000 µg/ml). The concentration of stock solution  
is further diluted with phosphate buffer solution  (PBS) pH 7.4 to form secondary 
solution resulting in the concentration of 100 µg/ml and to prepare solution with 10 
µg/ml concentration and scanned at different wavelength range of 200 – 400 nm in an 
UV spectrophotometer (Shimadzu UV-1700 pharma spec, Japan). From the 
absorbance of the resulting solution λmax is determined. 
3. Preparation of calibration curve using phosphate buffer solution (PBS) pH 7.4 
containing 0.15 % SDS: 
From the above prepared secondary stock solution2ml, 4ml, 6ml, 8ml, 10ml, 
12ml, 14ml 16ml, 18ml, 20ml samples are pipetted into 100 ml volumetric standard 
flasks separately and made up to the volume with Phosphate buffersaline pH 7.4 
containing 0.15% SDS to get concentrations of 2 μg/ml, 4 μg/ml,6 μg/ml, 8 μg/ml, 10 
μg/ml, 12 μg/ml, 14 μg/ml, 16 μg/ml, 18 μg/ml, 20 μg/ml of drug solutions 
respectively. The absorbance of the solutions is measured by using Ultraviolet visible 
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(UV) spectrophotometer (Shimadzu UV-1700 pharma spec, Japan) at λmax 239 nm. 
Calibration curve is plotted by using concentration in x – axis and absorbance in y – 
axis(Singla. N et al.,2009). 
B) COMPATIBILITY STUDIES FOR DRUG AND LIPID: 
For the development of formulation dosage form, preformulation studies is 
carried out to confirm no interaction exist between the drug and excipients. It gives 
information needed for selection of excipients with the drug for the formulation of 
nanodispersion. Infrared spectrophotomeris used to check the compatibility studies 
between lipids (glycerylmonostearateglycerylbehenate, stearic acid, 
glycerylmonooleate, capryol, & oleic acid ) and drug. 
1. Infrared (IR)Spectroscopic studies: 
The spectroscopic studies are carried out to find the interaction between pure 
drug, lipids and surfactants and its physical mixture by KBr pellet technique using 
FTIR spectrophotometer (shimadzu, RX 1, Japan). The IR spectrum of the best 
formulation is then compared with the spectrum of pure drug  (Simvastatin ) to assess 
the compatibility of the excipients and drug. The scanning range is 450-4000 cm-1 and 
the resolution is 4cm-1(Senthilnathan .B et al.,2011, Priyanka& Abdul HasanSathali 
A., 2012). 
C) FORMULATION OF SIMVASTATIN LOADED NANOSTRUCTURED 
LIPID CARRIER: 
Simvastatinloaded nanostructured lipid carrier is prepared by modified method 
ofhot homogenization followed by ultrasonication. 
Briefly, thelipophilic and hydrophilic surfactants were added into the lipid 
phase containing the solid lipid and liquid lipid (70:30). The lipidphase is melted at 
approximately 5 - 10°C above its melting point to avoid recrystallisation of the lipid 
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phase. The volume of water was halved. The volume of the first water potion was 
adjusted to have the same volume as the lipid phase. The volume of the second water 
portion was not adjusted. 
The first portion of the water was heated to the same temperature of lipid 
mixture to prevent recrystallisation of lipid phas. Then 1% w/w of  simvastatin  was 
added into the melted lipid phase followed by the addition of first hot-water portion 
immediately into the lipid phase . The mixture of drug, lipid phase, and the water 
phase was homogenized at 2000 rpm by using mechanical stirrer for 60 min. 
During the homogenization process, the second water portion (25º) was added 
slowly to the mixture to form the pre-emulsion. Then the pre-emulsion is allowed to 
cool to room temperature and stirred at 400 rpm for 30 min. 
Then it is ultrasonicated using a probesonicator processor for 10 min. Finally, 
the NLC dispersion was cooled rapidly in an ice bath to 25°C (Loo Chew Hung et al., 
2011) 
D) CHARACTERIZATION OF SIMVASTATIN LOADED 
NANOSTUCTURED LIPID CARRIER (NLC ): 
All the formulated Simvastatinloaded nanostructured lipid carrier are 
evaluated for its drug content, entrapment efficiency, particle size, polydispersity 
index, zeta potential, in vitro drug release and kinetics of drug release. 
1. Determination of Physicochemical properties: 
The NLC dispersion is to characterize for physicochemical properties such as 
color, odor and stability after centrifugation (2000 rpm for 30 minutes). 
2. Determination of drug content: 
The total drug content of NLC dispersion is determined by spectrophotometric 
analysis. One milligram equivalent of Simvastatin loadedNLC dispersion is dissolved 
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in (1 ml) ofmethonol and is suitably diluted withpH 7.4 saline phosphate buffer  to 
make 10 µg/ ml concentration. The absorbance is measured at 239 nm (λmax) using 
UV spectrophotometer (Shimadzu UV-1700 pharma spec, Japan). From the 
absorbance the drug content(Premanand .A et al., 2012,  Senthilnathan .B et al.,2011) 
is calculated using the formula given below, 
Sample absorbance 
  Drug content    =   -------------------------------   X 100 
     Standard absorbance 
3. Determination of drug entrapment efficiency: 
Simvastatin loaded NLCformulations (1 ml) are centrifuged at 14,000 rpm for 
90 minutes at 4ºC using a refrigerated centrifuge (Eppendorf, 5417R, Germany) in 
order toseparate the amount of Simvastatin encapsulated in the NLC from the unentraped 
drug.The free drug concentration in supernatant layer after centrifugation is 
determined at λmax (239 nm) using UV Spectrophotometer (UV-1700 Shimadzu 
corporation, Japan)  
The % entrapment efficiency is calculated by the following formula: 
  Total amount of drug taken -   Unentraped drug  
%EE   =  ------------------------------------------------------------------  X  100. 
                          Total amount of drug taken      
(Gambhire M.S et al., 2011, Priyanka& Abdul HasanSathali A et al., 2012,Dilip Patel 
et al., 2012) 
4. In vitro release studies: 
In vitro release of Simvastatin from Simvastatin  loadednanostructured lipid 
carrier formulation is determined by using dialysis bag diffusion technique  using pH 
7.4 saline phosphate buffer solution as dissolution medium.  
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Dialysis membrane with pore size of 2.4 nm and molecular weight cut off 
between 8000 – 13,000 Da is used which could retain NLCs and allow the diffusion 
of free drug into the dissolution medium. The bags are soaked in distilled water for 24 
h before use. The nanosuspension equivalent to (10 mg) of Simvastatin(approximately 
0.85 ml) is placed in dialysis bag and sealed at both ends. The dialysis bag is 
immersed in receptor compartment containing 100 ml of pH 7.4 phosphate buffer 
solutions in 250 ml beaker maintaining at 37°C ± 2°C and magnetically stirred at 100 
rpm. Samples withdrawn at predetermined time intervals of 30 min for first 2hrs  and 
every 60 min for 10 hrs. Sink condition is maintained by replacing with fresh 
phosphate buffer solution. The content of Simvastatin in the samples is determined by 
UV spectrophotometer (Shimadzu UV-1700 pharma spec, Japan) at 239 nm. All the 
operations are carried out in triplicate and the average values were taken (Medha 
Joshiet al., 2008, Nisha .N & Abdul HasanSathali.A et al., 2012, Premanand .Aet al., 
2012, Gambhire M.S et al., 2011). 
5. Kinetics of drug release 
In order to investigate the drug release mechanism from NLC formulations, 
the percentagecumulative drug release data is analyzed with following mathematical 
model. 
• Zero-order 
• First order 
• Higuchi 
• Hixson-Crowell cube root law 
• Korsmeyer-peppas model. 
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• The zero order rate Equation describes the systems where the drug release 
rate is independent of  its concentration. 
Qt = Q0 + K0t 
 Where,Qt is the amount of drug dissolved in time t,Q0 is the initial amount of 
drug in the solution (mosttimes, Q0= 0) and K0 is the zero order release 
constantexpressed in units of concentration/time.To study the release kinetics, data 
obtainedfrom in vitro drug release studies are plotted ascumulative amount of drug 
released versus time 
•The first order Equation describes the release from a system where the 
release rateis concentration dependent. 
log C = log C0–kt / 2.303    
Where C is the concentration of the drug at time (t), C0 is the initial 
concentration of the drugand k is the first-order release rate constant.Thedata obtained 
are plotted as log cumulative percentageof drug remaining vs. time. 
• Higuchi described the release of drugs from porous, insoluble matrix as a 
square root oftime dependent process based on Fickian diffusion as shown in 
following Equation. 
    Q = kt1/2 
Where Q is the amount of drug released in time t.This model is based on the 
hypotheses that (i) initialdrug concentration in the matrix is much higher thandrug 
solubility; (ii) drug diffusion takes place onlyin one dimension (edge effect must be 
negligible);(iii) drug particles are much smaller than systemthickness; (iv) matrix 
swelling and dissolution arenegligible; (v) drug diffusivity is constant; and (vi)perfect 
sink conditions are always attained in therelease environment.The data obtained are 
plotted as cumulative percentagedrug release versus square root of time 
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•Hixson and Crowell (1931) recognized that the Particles’ regular area is 
proportional to the cuberoot of its volume. They derived the equation 
W01/3 –Wt1/3 = κ t 
Where W0 is the initial amount of drug in the pharmaceuticaldosage form, Wt 
is the remaining amountof drug in the pharmaceutical dosage form at time tand κ 
(kappa) is a constant incorporating the surface-volumerelation.The equation describes 
therelease from systems where there is a change in surfacearea and diameter of 
particles. Tostudy the release kinetics, data obtained from in vitro drug release studies 
are plotted as cube root ofdrug % remaining in matrix vstime. 
•Korsmeyer – Peppas model describes the fractionof drug release relates 
exponentially with respect to time. 
Mt / M∞ = Ktn 
Where Mt / M∞is a fraction of drug released at timet, k is the release rate 
constant and n is the release exponent.In this model, the value of n characterizes 
therelease mechanism of drug. To study the release kinetics,data obtained from in 
vitro drug release studies areplotted as log cumulative percentage drug 
releaseversuslog time  
Release exponent (n) 
Drug transport 
mechanism 
Rate as a function of 
time 
0.5 Fickian diffusion t - 0.5 
0.45 < n = 0.89 Non – Fickian transport t n – 1 
0.89 Case II transport Zero order release 
Higher than 0.89 Super case II transport t n – 1 
 
(Suvakanta Dash et al., 2010) 
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6. Particle size and zeta potential: 
Particle size (z- average diameter),  polydispersity index (as a measure of the 
width of the particle size distribution) and zeta potential(to characterize surface 
charge of particle and physical stability of colloidal dispersions)  of Simvastatin 
loaded NLC dispersion is performed by dynamic light scattering also known as 
photon correlation spectroscopy(PCS) using a Malvern Zetasizer 3000 Nano ZS 
(Malvern instruments, UK) at 25°C. 
Prior to measurements all samples are diluted using ultra – purified water to 
yield a suitable scattering intensity. The diluted nanoparticle dispersion is poured into 
the disposable sizing cuvette which is then placed in the cuvette holder of the 
instrument and analysed.  Air bubbles, if any is removed from the capillary before 
measurement. All measurements is performed in triplicate.(MakarandGambhireet al., 
2011, PornthidaRiangjanapateeet al., 2012). 
7. Selection and evaluation of best formulation 
The best formulation selection based on the results obtained from particle size, 
entrapment efficiency, in vitro release studies and kinetics of drug release. 
a. Infrared (IR)spectroscopic studies: 
Infrared spectrum analysis is carried out to find out the interactions between 
the drug and excipients used as per the procedure mentioned on drug and lipid 
interaction studies. 
b. Morphology of NLC by Scanning electron microscopy (SEM) technique: 
Scanning electron microscopy is an excellent tool for physical observation of 
morphological features of particle both initially and degradation process. It is helpful 
to examine particle shape and surface characteristics such as surface area and bulk 
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density. The formulations are poured in a circular aluminum stubs using double 
adhesive tape, and coated with gold in HUS – 5GB vaccum evaporator and observed 
in Hitachi S – 3000N SEM at an acceleration voltage of 10 Kv and a magnification of 
5000X.  
E. FORMULATION OF SIMVASTATIN LOADED NLC BASED HYDROGEL  
On the basis of particle size, entrapment efficiency and in-vitro release studies, F15 is 
selected for the preparation of topical gel system.   
For the preparation of blank HG, Chitosan was dispersed in 1 % acetic acid 
solution and subsequently, Glycerine 1.5 ml was added to the aqueous solution,. The 
mixture was stirred manually for 10 minutes and sonicated to remove air bubbles. The 
formed hydrogel was left equilibrating for 48 hours in a sealed container at room 
temperature. Alasarra (2009) and Cao et al.(2009). Pure drug and NLC 
dispersionswere incorporated into the blank HGs, using a high speed stirrerat 1000 
rpm for1 min, in a concentration of 50% of the dispersion in the gel to yield plain gel 
and NLC based HG respectively (Ibrahim A.Alsarra ., 2009, Silva A.C et al., 2012 
F. EVALUATION OF THE PREPARED SIMVASTATIN NLC BASED 
HYDROGEL: 
1.Determination of Physicochemical properties: 
The hydrogels were characterized for physicochemical properties such as 
appearance, pH, texture analysis and stability. 
2.pH measurements 
The pH of the gel formulations are determined by dissolving 1g of gelin 10 ml of 
distilled water using a  pH  meter. Measurements are performed at 1st,  15thand 30th  
day after preparation to detect any pH fluctuations (ShindeAnilkumar .J et al., 2011) 
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3.Drug content 
One gram of gel formulation which contains approximately 5mg of drug is dissolved in 
(10 ml) of methanol. The resultant mixture is filtered through membrane filter (pore size 
0.45 mm) and is suitably diluted with pH 7.4 saline phosphate buffer containing 0.15% 
SDS to make 10 µg/ ml concentration. The absorbance is measured at 239 nm (λmax) 
using UV spectrophotometer (Shimadzu UV-1700 pharma spec, Japan) 
(GajananShindeet al., 2013). 
4.Texture Analysis 
 The   viscosity    of   topical   NLC based gel formulation is animportant factor 
in    determining   residence time of the drug in the skin. The viscosity determination 
is carried out by Texture Anayser TA- XT Plus (Stable Microsystems, UK) with the 
accessory Back extrusion cell, with 35mm disc and extension bar using 50 kg load 
cell 
TA Settings: Mode: Measure Force in Compression 
  Option: Return to Start 
  Pre-Test Speed: 1.5 mm/s 
  Test Speed: 2.0 mm/s 
  Post-Test Speed: 2.0 mm/s 
  Distance: 20mm 
  Trigger Type: Auto - 10g 
  Tare Mode: Auto 
  Data Acquisition Rate: 250pps 
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Method : Tests were carried out in a standard size back extrusion container (50mm 
diameter), approximately 75% full, immediately after removal from storage at a 
specific temperature e.g. 25C. The extrusion disc (35 mm) was positioned centrally 
over the sample container. For comparison of cohesiveness and 'work of cohesion' the 
probe was returned to the same position above the samples after each test.  The 
averages of three readings are used to calculate the viscosities of formulations(Autio, 
K et al., 2003) 
When a 10g surface trigger is attained (i.e. the point at which the disc's lower 
surface is in full contact with the product) the disc proceeds to penetrate to a depth of 
20mm. At this point (most likely to be the maximum force), the probe returns to its 
original position. The 'peak' or maximum force is taken as a measurement of firmness 
- the higher the value the firmer is the sample. The area of the curve up to this point is 
taken as a measurement of consistency - the higher the value the thicker the 
consistency of the sample.  
The negative region of the graph, produced on probe return, is as a result of 
the weight of sample which is lifted primarily on the upper surface of the disc on 
return, i.e. due to back extrusion and hence gives again an indication of 
consistency/resistance to flow off the disc. The maximum -ve force is taken as an 
indication of the cohesiveness of the sample - the more negative the value the more 
'cohesive' is the sample. The area of the negative region of the curve may be referred 
to as the 'work of cohesion' - the higher the value the more resistant to withdrawal the 
sample is which is an indication of the cohesiveness and also consistency/viscosity of 
the sample.  
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5.Ex vivo skin permeation studies 
Ex vivo skin permeation of of Simvastatin NLC based Hydrogelare studied using  
locally fabricated Franz diffusion cell with an effective permeation area and the 
receptor cell volume  2.54cm2 and 15ml respectively. 
Rats (male albino) 6 to 8 weeks old, weighing 150 to 200g are sacrificed for 
abdominal skin. After removing the hair the abdominal skin is separated from the 
underlying connective tissue with scalpel. The excised skin is placed on aluminium 
foil and the dermal side of the skin is gently teased off for any adhering fat and/or 
subcutaneous tissue. The skin is checked carefully to ensure the skin samples are free 
from any surface irregularity such as fine holes or cervices in the portion that is used 
for transdermal permeation studies. The ex vivostudy was approved by the 
institutional ethical committee. 
The skin is mounted between donor and receptor compartment with the stratum 
corneum side facing upward into the donor compartment. Phosphate buffer saline pH 
7.4 is filled in the receptor compartment. The NLC based gel formulation is applied 
on the skin in donor compartment which is then covered with aluminium foil to avoid 
any evaporation process. Sample is withdrawn through the sampling port of diffusion 
cell at predetermined time intervals for 12 hours, diluted to 10µg/ml concentration 
with phosphate buffer saline pH 7.4 and analyzed for drug content by UV-Visible 
spectrophotometer at λmax. The receptor medium is immediately replenished with 
equal volume of fresh medium. 
Similar experiments are performed for Simvastatin plain gel.  Experiments are conducted in 
triplicate. Sink condition is maintained for all the experiments. The percentage of drug release 
is plotted against time to find the drug release pattern (Gajanan S Sanapet al., 2013,Dilip 
Patel et al., 2012) 
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6.Drug deposition study: 
After 24 hrs release study, drug remained on skin was determined by scraping 
and then washing skin 3-4 times with diffusion medium and mixed. These washing 
were filtered through 0.45μ filter. This sample was analyzed by diluting with medium 
to make 10 µg/ ml and absorbance was measured at 239 nm using UV-VIS 
spectrophotometer (Shimadzu UV-1700 pharma spec, Japan). The same procedure 
was performed for NLC Based HG & plain HG formulations. At the end of 24 h, drug 
deposited in skin was also determined. A skin was cut into small pieces, homogenized 
and extracted with methanol and suitably diluted using pH 7.4 saline phosphate buffer 
and analyzed spectrophotometrically at 239nm. 
7. Ex vivo release kinetics 
The procedure for ex vivo release kinetics is the same as in vitro release kinetics 
study and is already discussed. 
8.Invivo Diabetic Wound healing activity 
The study was approved by the institutional animal ethics committee of KM 
college of pharmacy, Madurai with proposal number of 
IAEC/125/KMCP/261220708/2013-2014 which is constituted as per CPCSEA 
(Committee for the Purpose of Control and Supervision of Experiments in Animals) 
guidelines. The studies are conducted on albino rats of either sex, weighing 200 ± 20 
g. are selected Over Night fasted rats were made Diabetic by Single injection of 
Allaxon. Seven days later, rats with blood glucose levels between 300-400mg/dl were 
selected for invivo evaluation. The selected animals were divided into 3 groups with 6 
animals in each group. The first was a control group that is treated with NLC based 
gel without drug. The other was the test groups and received the prepared gels. 
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The back of the mouse was shaved and then sterilized using an alcohol swab. 
Wounds of approximately 2cm2 in surface area and 2mm in depth were made with 
sterile scalped on the shaved area of the back skin below the shoulder blades under 
light ether anesthesia. A wound placed in this area cannot be reached by the animal 
and therefore prevent self-licking. The wounding day was considered as day zero. The 
wound area treated with topical application of prepared gel (100mg once daily) till the 
wounds were completely healed. 
A measurement of the healed wound area as well as that unhealed was carried 
out by tracing the wound areas on butter paper and was replicated on a graph paper, 
from that the areas were measured bysquare counting procedure. The number of 
squares (0.01cm2) that appear completely (Nc) and partially (Np) inside thetracing 
were counted and area was determined using the followingformula: Ac+p= 
(Nc+0.4xNp) x 0.01.The wounds are monitored and the area of wound was monitored 
from the wounding day followed by 4,7,10 & 12th day. The percentage of wound 
contraction is calculated as the following. 
Wound area on day (zero) - Wound area in day (n)  
% of wound contraction =‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ x100  
Wound area on day (zero) 
GROUP-1(STANDARD GROUP) 
Animal were treated with NLC based hydrogel without drug 
GROUP-2(STANDARD GROUP) 
Animals were treated with Simvastatin plain gel 
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GROUP-3(TEST GROUP) 
Animals were treated with gel Simvastatin NLC based Hydrogel  
( UsamaFarghalyAly., 2012, Ibrahim A. Alsarra., 2009, Schubert V., 1997) 
9. Skin Sensitivity Test : 
Rats (200 -250 g ) of either sex used for testing of skin irritation. The animals 
were maintained on standard animal feed and had free of water. The animals were 
kept under standard conditions. Hair was shaved from back and area of 4 cm
2 
was 
marked on both the sides, one side served as control while the other side was test. Gel 
was applied (500 mg/animal) twice a day for 7 days and the site was observed for any 
sensitivity and the reaction if any, was graded as 0, 1, 2, 3 for no reaction, slight 
patchy erythema, slight but cofluent or moderate but patchy erythema and severe 
erythema with or without edema, respectively(UsamaFarghalyAly., 
2012,GajananShindeet al., 2013). 
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CHAPTER X  
RESULTS AND DISCUSSION 
 
A) STANDARD CURVES  FOR SIMVASTATIN 
1. Preparation of calibration medium 
 The calibration medium of phosphate buffer saline PBS pH 7.4(with 0.15% 
SDS) was prepared as per Indian Pharmacopoeia., 2010. 
 
2. Determination of (absorption maximum) λmax 
 The absorption maximum (λmax) of the Simvastatin was estimated by 
scanning the drug solution (10 µg/ml) between 200-400 nm regions in the UV 
spectrophotometer. The obtained spectrum showed that the absorption maximum 
(λmax) at 239 nm in PBS pH 7.4 (with 0.15% SDS). The absorbance spectra was 
shown in Figure 1A. 
 
3.Preparation of calibration curve using phosphate buffer (PBS) pH7.4 with 
0.15% SDS 
 The standard calibration curve of Simvastatin was prepared by measuring the 
absorbance of drug at different concentrations (2-20 μg/ml) using PBS pH 7.4 (with 
0.15% SDS). The absorbance of solution was measured at λ max of 239nm.Simvastatin 
obeys the beer’s law within the concentration range of 2-20 μg/ml.From the 
calibration curve the correlation coefficient was found to be 0.99961. The calibration 
readings were shown in Table 1 and calibration plot of Simvastatinwas shown in 
Figure 1B (Singla N et al 2009). 
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B) COMPATIBILITY STUDIES FOR DRUG AND LIPID 
1. Infrared (IR) Spectroscopic studies  
IR spectroscopy was used to investigate the interactions between lipid, drug 
and other excipients. The results of IR Spectra of pure drug, lipidic excipient and 
physical mixture of lipid and drug were shown in the Figure 2A- 2I.The FT-IR 
spectral analysis of Simvastatin alone showed that the principal peaks were observed 
at wave numbers 3551.07, 3011.95, 1725.38, and 1654.01. 1455.34, 1390.72, and 
841.96cm-1 (Figure 2A) confirming the purity of the drug 
S.NO FUNCTIONAL GROUPS 
OBTAINED WAVE 
NUMBER 
1 Saturated Ketones (C=O) 1725.38 cm-1 
2 C=C stretching 1455.34 cm-1 
3 C-(CH3)2 1390.72 cm-1 
4 β – Ketonic ester (COO) 1654.01 cm-1 
5 C=CH 3011.07 cm-1 
6 Aromatic C=O 1697.41 cm-1 
7. Benzene Ring 1466.91 cm-1 
 
 In the FT-IR spectra of the physical mixture of simvastatin, lipids, surfactant 
and chitosan,   the major peaks of Simvastatin were observed at wave numbers 
3551.07, 3011.95, 1454.38, and 1725 cm-1. However, some additional peaks were 
observed with the physical mixture, possibly because of the presence of lipids. (Rahul 
Nair et al., 2011).It was confirmed that there are no major shifting as well as no loss 
of functional peaks between the spectra of drug and the physical mixture. Hence the 
drug and lipid are compatible with each other. 
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C) FORMULATION OF SIMVASTATIN LOADED NANOSTRUCTURED 
LIPID CARRIERS (NLCs) 
The Simvastatin loaded NLC were prepared by hot homogenization followed 
by ultra sonication method.The initial location of the surfactants greatly influences the 
properties of the emulsion.A double emulsion is formed during the emulsification 
process by initially placing the surfactants in the lipid Phase and yielded a very good 
emulsion with uniform particle size distribution (Lin et al., 1975). In addition to the 
high-temperature effect, the cooling of the pre-emulsion after homogenisation 
contributes to the narrow particle size distribution for the pre-emulsion which agrees 
with the finding of Marie P et al., 2002 
Previouslyit was reported that the improved drug entrapment efficiency and an 
increased stabilitywith mixure of solid lipids & liquid lipids in the ratio of 70:30.So 
the NLC composed of lipids at different concentration (3%,5% and 7%) and different 
percentage of lipid phase surfactant (Phospholipon 90G -1%,2% and 3%) were 
prepared. The compositions of the formulations are shown in Table 2A-2Cresulted a 
stable, uniform and homogenous dispersion of NLCs.  
 
i) Impact of lipidson NLC formulations 
The excipients selected were needed to be pharmaceutically acceptable, 
nonirritating, and nonsensitizing to the skin and to fall into the GRAS (generally 
regarded as safe) category for the formulation of NLCs. Selecting matrix lipids and 
stabilizers based on solubility can help formulating NLC with good storage stability 
and a high E.E., Blending a solid lipid with a liquid lipid leads to a less ordered solid 
lipid matrix providing the possibility for a high drug payload (Hu et al., 2006; Muller 
et al., 2002).A range of solid lipids (stearic acid, Glyceryl mono stearate and 
compritol) , liquid lipids (capryol, oleic acid andGMO) and surfactants (Tween 80) 
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were selected which had the highest solubility of  Simvastatin in previously repoted 
research works (HanaaMohmoudet al., 2013; Jie Lai et al., 2009; 
ii) Impact of surfactant on NLC formulations 
The amount emulsifier should be optimum to coverthe surface of the 
nanoparticles and the right blend of low and high hydrophilic lipophilic balance 
surfactants leads to the formation of a stable nanoemulsion formulation. (Prachi B. 
Shekhawat., 2013). Among the various surfactants evaluated, the maximum solubility 
of Simvastatin was found in Tween 80 so it was selected as aqueous phase 
surfactant(SarfarazAlam Md.et al., 2012) and the addition of phospholipid reduces the 
possibility of drug loss to the external phase, and provides more space to incorporate 
the drug, resulting in improved entrapment efficiency. This may also be due to an 
excess of phospholipid possibly forming multilayers around the particle (Shah KA et 
al.,2007).So the impact of  Phospholipon 90G on EE at various concentration was 
investigated by using Phospholipon 90G as lipophilic surfactant. 
D) CHARACTERIZATION OF SIMVASTATIN LOADED 
NANOSTRUCTURED LIPID CARRIER (NLC) 
1. Determination of Physical properties 
 The NLC dispersion was milky white in appearance, odorless, and fluid in 
nature. It was stable and did not show sedimentation even after centrifugation (2000 
rpm for 30 minutes). 
2. Determination of drug content 
  The percentage drug content for all the formulations (F1-F27) shown in the 
Table 3.  The drug content was found in the range of 92.87% - 94.74% indicating 
uniform distribution of drug in the formulation. 
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3. Determination of drug entrapment efficiency (EE) 
 In order to attain optimal encapsulation efficiency, several factors were varied 
including the type and concentration of the lipid and concentration of lipid phase 
surfactant material used. In all the formulations, the impact of lipid and surfactant 
concentration was significant. The results of EE were shown in the Table 4A-4C and 
Figure 3.  
The EE of the formulations F1-F3 (glycerylmonostearate&capryolat  3% and 
phospholipon 90G at 1% - 3% as surfactant) showed 29.38%  - 41.26%; for the 
formulations F4-F6 (glycerylmonostearate&capryol at  5% and phospholipon 90G at 
1% - 3% as surfactant) showed 33.43% - 43.14% and for the formulations F7-F9 
(glycerylmonostearate&capryol at  7% and phospholipon 90G at 1% - 3% as 
surfactant) showed 40.74% - 54.13%.  
The EE ofthe formulations F10-F12 (stearic acid & oleic acid at  3% and 
phospholipon 90G at 1% - 3% as surfactant) showed 25.61% - 41.87%; for the 
formulations F13-F15 (stearic acid & oleic acid at  5% and phospholipon 90G at 1% - 
3% as surfactant) showed 29.18% - 40.64%,  andfor the formulations F16-F18 (stearic 
acid & oleic acid at 7% and phospholipon 90G at 1% - 3% as surfactant) showed 
37.77% - 49.72%  
The EE of the formulations F19-F21 (compritol and GMO at  3% and 
phospholipon 90G at 1% - 3% as surfactant) showed 41.98% - 52.84%, forthe 
formulations F22-F24 (compritol and GMO at  5% and phospholipon 90G at 1% - 3% 
as surfactant) showed 52.12 - 62.16% (F22-F24) at 5% and forthe formulations F25-
F27 (compritol and GMO at  7% and phospholipon 90G at 1% - 3% as surfactant) 
showed 56.05 - 67.76%. 
The influence of surfactant and lipid concentration discussed below. 
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i) Influence of surfactant on entrapment efficiency 
 The effect of lipid phase surfactant (Phospholipon 90G) on the entrapment 
efficiency of Simvastatin loaded Nanostructured lipid carrier were investigated. The 
results were shown in Table 4A-4C. 
From the results it was observed that the influence of surfactant was more 
pronounced on entrapment efficiency apart from particle size from the production 
process, the physical long-term stability during storage and drug release profiles.  
Among the formulations F1-F9 (GMS &capryol  as lipids)  the maximum 
entrapment efficiency was obtained for the formulations F3, F6 and F9 and it was 
found to be41.26%, 43.14% and 54.13%  at  3%, 5% and 7% of lipids respectively. 
Among the formulations F10-F18 (Stearic acid & oleic acid as lipids)  the 
maximum entrapment efficiency was obtained for the formulations F12, F15and F18 
and it was found to be41.87%, 40.64% and 49.72% at3%, 5% and 7% of lipids 
respectively 
Among the formulations F19-F27 (compritol& GMO as lipids) the maximum 
entrapment efficiency was obtained for the formulations F21, F24 and F27the EE was 
found to be 52.84% , 62.16% and 67.76at 3%, 5% and 7% of lipids respectively, 
while remaining batches showed less entrapment efficiency.  
From the prepared NLC formulations, it was observed that an increase in 
Phospholipon 90G concentration increases EEand the formulations containing 
Phospholipon 90G at 3% showed higher entrapment irrespective of the lipids 
composition. 
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ii) Effect of lipid material on entrapment efficiency  
It could be noted that thelipid concentrationalso influenced the entrapment 
efficiency of NLC. It was based on the length of carbon chain atom and melting point 
of lipids.  
The EE of the formulations F 1- F 9 containing GMS&capryolranging from 
29.38 - 54.13%, for the formulations F 10- F 18 containingstearic acid & oleic acid 
ranging from 25.61- 49.72 % and for the formulationsF 19- F 27 containing compritol 
ATO 888 & GMO ranging from 41.98 – 67.76 %.  
The results indicated that, increasing the lipid concentration also increases the 
EE.  This may be due to the reason that the higher concentration of lipid would 
provide more space to increment of the lipid content and also reduces the escaping of 
drug into the external phase thus ensuring highest EE. 
The EE of the three lipids was in the order of  
Compritol>Glycerylmonostearate> Stearic acid. 
Among the lipids used, compritol showed the highest EE when compared to 
glycerylmonostearate and stearic acid. This may be due to the fact that the presence of 
long chain fatty alcohol could lead to the creation of a less ordered solid lipid matrix 
and leaves enough space to accommodate drug molecules(Compritol molecular 
formula (MF): C25H52O6, glycerylmonostearate MF: C21H42O4 and stearic acid MF: 
C18H36O2) (Priyanka and Sathali., 2012). 
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4. In vitro release studies 
From the results, it was observed that simvastatin loaded Nanostructured lipid 
carrier containing three different lipids (GMS, Stearic acid and compritol ATO 888) 
displayed a biphasic drug release pattern with a burst release within 2 hours followed 
by sustained release. The values are shown in Table 5A-7C and Figure 23A-23C.  
Initial burst effect 
The initial burst effect of the formulations containing glyceryl mono stearate 
&capryolvaried from 39.63% – 30.58 % (F1-F3) at 3%; 34.69% – 29.18% (F4-F6) at 
5% and 30.73% – 26.01% (F7-F9) at 7% using phospholipon 90G at 1% - 3% as 
surfactant.  
The initial burst effect of the formulations containing stearic acid& oleic acid 
varied from 43.16% – 31.59 % (F10-F2) at 3%; 38.09% – 32.21% (F13-F15) at 5% 
and 32.63% – 26.32% (F16-F18) at 7% using phospholipon 90G 1% - 3% as 
surfactant.  
The initial burst effect of the formulations containing compritol and GMO 
varied from 30.03% – 25.69 % (F19-F21) at 3%; 27.69% – 23.46% (F22-F24) at 5% 
and 25.85% – 21.68% (F25-F27) at 7% using phospholipon 90G 1% - 3% as 
surfactant.  
The initial burst release might be due to the presence of unentrapped drug in 
the NLC dispersion. Another reason might be due to most of the liquid lipid being 
located in the outer shell of the nanoparticles, the oleic acid-enriched outer layers 
possessed a soft and considerably higher solubility for lipophilic drugs, which 
ultimately increased the loading of the drug which lead to a drug-enriched shell and 
could be easily released by diffusion or matrix erosion that is related to burst release 
at the initial stage  (Hu QF et al 2005) . 
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The other possible explanation for the observed burst release is the large 
surface area of Simvastatin-loaded NLC as well as the short diffusion distance for 
Simvastatin from the particle matrix into the dissolution medium since the liquid lipid 
adheres to the lipid matrix which decreases the diffusion path length of the lipid 
matrix.(Müller et al., 2002b; Souto et al., 2004; zurMühlen et al., 1998). 
From the results higher lipid ratios and Phospholipon 90G - 3% as surfactant 
containing formulations showed lower release from the lipid due to higher entrapment 
efficient. 
 
Sustained effect 
 After the 2 hours burst release, NLC formulations showed sustained release at 
12 hours. The release of drug from the formulations containing 
glycerylmonostearate&capryol as lipids varied from 75.81%-67.84% at 3% (F1-F3); 
71.99%-64.72% at 5% (F4-F6) and 68.62%-59.79% (F7-F9) using phospholipon 90G 
at 1% - 3% as surfactant. 
The release of drug from the formulations containing stearic acid& oleic acid  
as lipidsvaried from 80.35%-69.83% at 3% (F10-F12); 77.25%-70.85% at 5% (F13-
F15)  and 72.28%-63.63.64% (F7-F9) using phospholipon 90G at 1% - 3% as 
surfactant.  
The release of drug from the formulations containing compritol& GMO as 
lipids varied from 67.82%-61.29% at 3% (F19-F21); 62.49%-56.61% at 5% (F22-
F24) and 60.63%-53.81% (F7-F9) using phospholipon 90G at 1% - 3% as surfactant. 
Among the three lipids used, compritol ATO 888 showed more sustained 
release than the staeric acid and glycerylmonostearate due to its longer carbon chain 
length than the other two lipids. The lower melting point lipid can produce a 
controlled release from NLC. This is due to the presence of solid solution throughout 
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the particle combined with the slow diffusion of drug from the lipid matrix (Priyanka 
and Sathali 2012). 
The order of drug release from the three lipids as follows: 
 Stearic acid >Glycerylmonostearate>Compritol.  
From the results it was concluded that higher lipid concentration decreases release 
rate. The nature of fatty acids affected the release significantly and longer the carbon 
chain length of fatty acids, the slower the drug release. From the results F27 
formulation containing compritol ATO 888 using phospholipon 90G -3% was showed 
sustained release due to higher entrapment efficiency and long chain carbon atom of 
lipid. 
Both burst release and sustained release are of interest for topical application. 
Burst release isuseful to improve the penetration of drug and for faster onset of action, 
while a sustainedrelease supplies the drug over a prolonged period of time. 
5. Kinetics of drug release 
 The kinetics and mechanism of drug release were studied by  release 
kinetics, the n, k and r2 values are indicated in the Tables 6A – 6C. Among the models 
tested, the drug release profile of all formulations F1-F27 were best fitted with first 
order with r2 values ranging from 0.854-0.993 and Higuchi model with r2 values 
ranging from 0.987 -  0.994. From the results higuchi release kinetics showed purely 
diffusion controlled. 
According to the data presented in the Tables 6A – 6C, the values of exponent 
n were in the range of 0.337- 0.551 which indicated that the drug release mechanism 
followed non-fickian model of release kinetics. 
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6. Particle size and zeta potential  
Particle size distribution plays a critical role in influencing the 
physicochemical and penetration mechanism of drugs into the skin (Soutoet al., 
2004). The particle size analysis of the NLC formulations was estimated by dynamic 
light scattering technique. Based on  the entrapment efficiency and in vitrorelease 
profiles of NLC dispersions, Nine formulations, three formulation from each set of 
lipids  (GMS &capryol – F3, F6, F9 and stearic acid & oleic acid – F12, F15, F18) 
and compritol& GMO - F21, F-24, F-27 at 3% , 5%, and 7% of lipid concentrations 
respectively) having higher entrapment and controlled release were selected for 
particle size analysis. Sizes of simvastatin loaded NLC were found to be in the range 
of 14.06 – 235.2 nm. The particle size values are shown in Table 7A-7C and the 
distribution curves were shown in Figure 6A- 6C.  
i)Influence of lipid concentration on particle size: 
The influence of different drug- lipid ratios of Simvastatin loaded 
nanostructured lipid carrier was investigated. 
Formulations F3, F6 and F9 prepared using different concentration of lipid 
(glycerylmonostearate&caryol) (3%, 5%and 7%) containing Phospholipon 90G (3%) 
as stabilizer showed the particle size of 118 nm, 54.01 nm and 108.1nm respectively. 
Formulations F12, F15 and F18 prepared using different concentration of lipid 
(staric acid & oleic acid) (3%, 5%and 7%) containing Phospholipon 90G (3%) as 
stabilizer showed the particle size of 53 nm, 14.06 nm and 44.05 nm respectively. 
Formulations F21, F24 and F27 prepared using different concentration of lipid 
(compritol& GMO) (3%, 5%and 7%) containing Phospholipon 90G (3%) as stabilizer 
showed the particle size of 217.8 nm, 94.43 nm and 235.2 nm respectively. 
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Particle size significantly increased with increasing concentration. Huge 
augmentation of particle size was observed at 7% lipid concentration. It was observed 
that at a particular surfactant concentration (3%), an increase in the lipid content 
decreased the particle size at an optimum concentration (5%) after which the particle 
size was increased. This is because the sonication energy more efficiently distributed 
in the dilute dispersion (i.e., lower lipid concentration) than the concentrated 
dispersion (i.e., higher lipid dispersion), which produced smaller particles at lower 
lipid concentration (Surajit Das et al., 2012). Larger particle size with increase in lipid 
content could be attributed to viscosity of inner phase that affected the shearing 
capacity of homogenizer, decrease in emulsifying efficiency and increase in particle 
agglomeration. 
From the results, it was further observed that the formulations containing 5% 
lipid concentration were selected and the particle sizes of other lipids at the same 
concentration were showed decrease particle size (glycerylmonostearate had the 
particle size of 54 nm where as stearic acid had 14.06 nm and compritol ATO 888 had 
94.43 nm particle sizes. 
Hence it was noted that the drug: lipid ratio was found to have a positive effect 
on particle size i.e. increase in lipid concentration resulted in larger mean particle 
sizes and broader size distributions.  
ii) Effect of different lipids on the particle size of simvastatin NLC 
There is a significant difference in the size of the particles with change in 
lipids. The decreasing order of particle size for the three lipids is as follows: 
 Compritol>Glycerylmonostearate> Stearic acid. 
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 Of the three lipids used stearic acid containing formulations showed lesser 
mean particle size than the glycerylmonostearate and compritol. This may be due to 
the tendency of  NLC to increase in size with the increase in carbon chain length of 
the lipids and higher melting point lipid (Compritol melting point, MP: 72°C, 
glycerylmonostearate MP: 60°C, and stearic acid MP: 55°C ). Compritol has a higher 
melting point than GMS and Stearic acid,  which results in slower lipid 
recrystallization from the hot homogenized condition resulting in increase in particle 
size. Hence, the higher the melting point of lipids the higher the particle size. 
From the results, formulation containing stearic acid at 5 % concentration was 
optimized to get an NLC formulation in nanometric size range. 
iii) Polydispersity index (PDI) 
The PDI for all the formulations as shown in Table 7A-7C and Figure 6A-6C . 
The PDI were in the range of 0.138 – 0.402 which is smaller than 0.5, which indicates 
a relative homogenous dispersion.Polydispersity index indicate the width of the 
particle size distribution, which ranges from 0 to 1. Theoretically, monodisperse 
populations indicates PI = 0. However, PI < 0.2 was considered as narrow distribution 
and those greater than 0.5 indicate high homogenicity. (Surajit Das te al., 2012). 
iv) Zeta potential (ZP) 
 The simvaststin loaded nanostructured lipid carrier were characterized to 
evaluate the effect of different lipids at different concentrations on surface charge of 
nanoparticles. The results were presented in Table 8 and Figure 7A – 7C. 
Zeta potential of formulations F1-F27 prepared with three different set of  
lipids (GMS,-capryol, stearic acid-oleic acid, compritol-GMO ) and phospholipon 
90G (3%) as lipid phase surfactant showed negative zeta potential (-11.63 mV to -
23.4 mV). 
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Zeta potential or electrophoretic mobility is an electric charge on particle 
surface forms electrical barrier which results in ‘Repulsion phenomenon’ is the zeta 
potential of a particular formulation (Shailesh S. Chalikwar., 2012). Most particles 
dispersed in an aqueous system will acquire a surface charge, principally either by 
ionization of surface groups, or adsorption of charged species. ZP is useful to predict 
the physical stability of NLC dispersion.  
It has been reported, that in a combined electrostatic and sterical stabilization a 
zeta potential of about -20 mV can be sufficient for physical stability (Jacobs and 
Muller 2002).All nanoparticles showed a high negative residual charge due to 
chemical nature of the lipid matrix (stearic acid/oleic acid/behenic acid) and 
surfactant used. Hence NLC have potential of physical stability as it has zeta potential 
of -13.6 – 23.4 mV which is near to -20 mV. Values of f potential showed prepared 
NLC have sufficient charge and mobility to inhibit aggregation of particles. 
7. Selection and evaluation of best formulation 
Based on entrapment efficienc, in vitro release and particle size 
 Based on entrapment efficiency the formulations containing phospholipon 
90G at 3% as surfactant showed  higher entrapment on lipids. Due to high entrapment, 
drug release from NLCs was sustained. According to these release profile 9 
formulations were selected. Among the 9 formulation 3 formulation showed smaller 
particle size at optimized 5% lipid concentration. From that F15 (stearic acid & oleic 
acid ) was selected as the best formulation because of its smallest particle size. 
 
a. Infrared (IR) spectroscopic studies  
 IR studies were carried out to confirm the compatibility between the drug, 
lipids and excipients for the above selected best formulations (F15). The IR peaks are 
shown in Figure 8. The major peak functional groups of simvastatin (3550.95, 
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3010.88, 2970.38, and 1724.36 cm-1) was obtained in the best formulations and no 
more additional of functional peaks were noticed.  
b. Morphology of SLN by Scanning electron microscopy (SEM) technique: 
 The SEM photograph of the selected formulation F15 was shown in 
Figure 9. The SLN dispersion showed the particle size was found to be less than 1µm 
in size with the spherical shape and almost smooth surface.(Priyanka and Sathali 
2012). 
E. FORMULATION OF  SIMVASTATIN LOADED  NLC  BASED 
HYDROGEL  
The overall objective of the present work was to develop a hydrogel dosage 
form containing simvastatin as a potential dermatological formulation. The selected 
best NLC formulation (on the basis of highest entrapment efficiency, controlled in 
vitro release and smaller particle size among the all formulations) was incorporated 
into suitable gel base (Chitosan as gelling agent 4%) to obtain 0.5% of the drug. Plain 
simvastatin gel was prepared by incorporating the drug into gel base to obtain same 
0.5% of the drug. Both the formulas were showed in Table 9. 
F. EVALUATION OF THE PREPARED SIMVASTATIN NLC BASED 
HYDROGEL 
1.Determination of Physicochemical properties 
The physical properties of the gel formulations are shown in Table 10. The 
physical appearances of all gel formulations were yellow in colour, 
translucent,smooth and homogeneous in texture. 
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2. pH measurement 
The results are shown in table No.10. The pH of the gel was measured  in between 5.3 
to 5.2 at  intervals of 0,15 ,30 th day respectively which is compatible with normal 
skin pH in healthy people (Hadgraft J. et al.,2001)That may be rendered its topical 
application to skin without irritation. It is important to say that there was no 
significant change in the pH values as a function of time for all formulations.  
3. Drug content 
 The drug content of the prepared gels was determined after lysing the 
nanoparticles with methanol. It was measured at 239 nm at UV-visible 
spectrophotometer, 1700-pharma spec, Japan. Drug content of the developed HG was 
found to be 96.51 % and 97.71% for NLC based gel and plain gel respectively. This 
indicated that the uniform distribution of drug in prepared gel formulations. The 
results were in shown Table 11.  
4. Texture analysis 
The mechanical parameters firmness and adhesiveness obtained by texture 
profile analysis for all tested semi-solid formulations are shown in Fig 10A – 10C. 
An ideal semi-solid formulation for topicall delivery should have a 
combination of high adhesiveness, in order to prolong the contact time to allow for 
the drug release and appropriate firmness, to facilitatelocal application.These 
parameters are directly influenced by the formulation viscosity. 
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Gel Batch Code 
Firmness 
(Kg) 
Cohesiveness 
(Kg.sec) 
Consistency 
(Kg) 
Index of viscosity 
(Kg.sec) 
PG 
0.166±0.00
9 
1.246±0.035 0.077± 0.006 0.404±0.05 
NG 
0.069±0.00
3 
0.629±0.031 0.042±0.003 0.268±0.014 
NLC (F15) 
0.010±0.00
1 
0.108±0.015 0.005±0.000 0.002±0.000 
 
From the tableN.o. 12, data indicative that the viscosity of the optimized NLC based 
HG formulation was enough to adhere on skin surface which increase the residence 
time, enhances penetration across the skin and thereby increase drug availability at 
site of action in controlled manner and the subsequent systemic absorption.Even 
thoughthe plain HG is firmer, more cohesive and of a thicker consistency than NLC 
based HG.the presence of NLC within the HGs allowed for obtaining a topical 
application form having the desired semi-solid consistency, with major properties of 
firmness, adhesiveness and enhancedspreadability. (Serra L et al., 2009,.Jones D.S et 
al., 1997, Jones D.S et al., 1999). 
5. Exvivo Skin permeation study  
Exvivo skinpermeation studies were performed to compare the permeation of 
drug from the optimized NLC, NLC Based HG and plain HG preparation from 
excised rat skin. The result of Skin permeation studies were portrayed in Figure 11and 
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table No.13, which shown drug release in 12 hrs. All of the formulations contained 
the same amount of simvastatin (5mg).  
           Fig. 11 shows the drug release profiles of 31.01% and 27.44% for NLC and 
NLC based HG, respectively, in the first 2 hour whereas it was only 14.53% for plain 
HG. The cumulative % drug release at 12 hours was 64.54%, 61.08% and 46.66% for 
NLC, NLC based HG and plain HG respectively.  
These differences could be explained by the higher viscosity of plain HG when 
compared to NLC based HG, since the drug release from semi-solid formulations is 
influenced by its rheological behaviour (Lippacher.Aet al., 2001). 
Furthermore, The NLC dispersions and NLC based HG formulations possessed a 
sustained drug release over a period of 12 h, but the sustained effect was more 
pronounced with NLC based HG formulations compared to optimized NLC, which 
could be related with the presence of the gel matrix, simvastatin release from the 
NLC-based HGs should be further delayed, due to the combined diffusionalresistance 
of both systems. The slower release of drug from NLC and NLC based gels 
maintained the drug concentration for longer period of time (Bhaskar K et al 2009). 
Moreover,The results of drug permeation from all the formulations through 
the rat abdominal skin confirmed that simvastatin was released and permeated 
through the rat skin and hence could possibly permeate through the human skin. 
6. Drug deposition study 
The result of skin deposition study was indicated in table n.o. 14. The 
Percentage of drug remained on the skin from NLC dispersion, NLC based HG and 
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plain gel was found to be 15.01%, 12.56% and 41.11% respectively, which shows that 
plain drug HG had poor penetration through the skin. 
 Percentage of drug retained into the skin from NLC dispersion, NLC based 
HG and plain gel was found to be 17.62%, 23.44% and 9.13% respectively. This 
shows the better penetration ability of NLC based HG and it was more than that of 
plain gel and NLC dispersions. Thus, drug-localizing effect in the skin seems possible 
with novel colloidal particulate drug carriers such as NLC. This colloidal carrier, 
being submicron in size, enhances the drug penetration into the skin, and because of 
its lipoidal nature, the penetrated drug concentrates in the skin and remains localized 
for a longer period of time, thus enabling drug targeting to the skin.  So from above 
result, it has been concluded that NLCBG induce better result had better compared to 
others (Pallavi V et al., 2006). 
7. Ex vivo release kinetics 
 To analyze the drug release mechanism in vitro release data was fitted into 
various release equations and kinetic models (Zero order, First order, Hixson – 
Crowell, Higuchi and Korsemeyer – Peppas models). The release kinetic data for all 
the formulations were shown in theTable15 and Figure 12A to 28E. 
Among the models tested, the drug release profile of all formulations F1-F27 
were best fitted with first order with r2 values ranging from 0.992-0.995 and Higuchi 
model with r2 values ranging from 0.986 -  0.995. From Table 15it can be concluded 
that, all formulations fitted very well to the Korsmeye–Peppas model with different 
R2 and n values, which means that the drug release processes were different. Classical 
Fickian diffusion was the release mechanism for NLC dispersion with n value of 
0.432 and anomalous non-Fickian (combination of diffusion and erosion mechanisms) 
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for both NLC based HG and plain HG with n value of 0.49 and 0.7 respectively. ( 
Ritger P.L. et al., 1987). 
8. Invivo Diabetic Wound healing activity 
Results of In-vivo wound healing studies were represented in figure 14A & 
14B. From the figure, it could be noticed that all NLC based HG treated groups 
showed a time dependant increase in % wound contractions which is significantly 
higher than any of the treated groups . 
By day 4, NLC based HG treated wounds were 48.29% healed compared with 
41.34% and 26.80% in the plain gel treated and control group respectively. 
 Eighty percent wound closure could be achieved within 7 days for those 
groups treated with NLC based HG. In contrast, control wounds with no drug healed 
more slowly and about 80% wound closure was achieved only after 12 days (Fig. 14A 
& 14B). There was no significant different between NLC based HG and plain gel 
treated groups (96.42% wound closure by day 12). It was also revealed that none of 
the rats in simvastatin treated groups showed scab formation but rats in control group 
showed formation of scab which delayed wound healing. 
The findings indicate that the wound healing in both NLC based HG and plain 
gel treated groups occurred faster than the control group, while complete wound 
closure, hair began to grow and the wounds area were completely covered with hair 
was observed on 12
th
day of wound induction in NLC based HG treated groups 
revealed that the NLC based HG had the superiority over other tested groups. 
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The results of the present study indicate that simvastatin promote the healing 
in diabetic wounds. This fast and higher wound contraction rate may be ascribed to 
the dual effect of the drug and the vehicle, chitosan HG.  
The prohealing effects of these drugs may be due to their proliferative activity, 
enhanced angiogenesis & endothelial nitric oxide release leading to increased blood 
flow in growing tissue. Its antioxidant property may also contribute to itsprohealing 
effect. Chitosan induced the migration of the inflammatory cells, formation of 
granulation tissue or re-epithelialization in the early stages of wound healing. And 
whenglycerin applied to the skin, signals the cells to mature in normal fashion, a 
hydrogel dressing of high glycerin content is better and more suitable to manage 
wound healing. In addition, glycerin is known to have humectants (Xiangjian Z et al., 
2003, Okan G et al., 2011)  
9. Skin irritation study  
The results of the skin irritation study revealed that the Nanostructured lipid 
carrier based gel exhibited considerably no signs of irritation or erythemas were 
noticed and all the animals tolerated the applied gels during the whole period of study. 
Therefore, it can be assured that the gel formulation can be used for topical 
application. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
TABLES AND FIGURES 
TABLE 1 
CALIBRATION OF SIMVASTATIN IN pH 7.4 SALINE PHOSPHATE 
BUFFER CONTAINING 0.15% SDS 
  
S. NO CONCENTRATION (μg/ml) ABSORBANCE ± SD* 
1 2 0.118 ±0.0151 
2 4 0.241 ±0.0127 
3 6 0.351 ±0.0104 
4 8 0.460 ±0.0172 
5 10 0.613 ±0.0115 
6 12 0.716 ±0.0116 
7 14 0.842 ±0.0145 
8 16 0.964 ±0.0030 
9 18 1.066 ±0.0053 
10 20 1.182 ±0.019 
 
   n=3*                                                                                       γ = 0.99961 
 
 
 
TABLE 2A:  COMPOSITION OF SIMVASTATIN NLC 
 
FORMULATION
CODE 
LIPID COMPOSITION SOLID LIPID : LIQUID LIPID 
RATIO 
DRUG -LIPID 
RAIO 
SURFACTANT 
CONCENTRATION 
SOLID 
LIPID 
LIQUID 
LIPID 
PHOSPOLIPON 
(% W/V) 
TWEEN-80 
(% W/V) 
F1 GMS CAPRYOL 70:30 1:3 1% 2% 
F2 GMS CAPRYOL 70:30 1:3 2% 2% 
F3 GMS CAPRYOL 70:30 1:3 3% 2% 
F4 GMS CAPRYOL 70:30 1:5 1% 2% 
F5 GMS CAPRYOL 70:30 1:5 2% 2% 
F6 GMS CAPRYOL 70:30 1:5 3% 2% 
F7 GMS CAPRYOL 70:30 1:7 1% 2% 
F8 GMS CAPRYOL 70:30 1:7 2% 2% 
F9 GMS CAPRYOL 70:30 1:7 3% 2% 
 
 
TABLE 2B:  COMPOSITION OF SIMVASTATIN NLC 
 
FORMULATION
CODE 
LIPID COMPOSITION SOLID LIPID : LIQUID LIPID 
RATIO 
DRUG -LIPID 
RAIO 
SURFACTANT 
CONCENTRATION 
SOLID LIPID LIQUID LIPID 
PHOSPOLIPON 
(% W/V) 
TWEEN-80 
(% W/V) 
F10 STEARIC ACID OLEIC ACID 70:30 1:3 1% 2% 
F11 STEARIC ACID OLEIC ACID 70:30 1:3 2% 2% 
F12 STEARIC ACID OLEIC ACID 70:30 1:3 3% 2% 
F13 STEARIC ACID OLEIC ACID 70:30 1:5 1% 2% 
F14 STEARIC ACID OLEIC ACID 70:30 1:5 2% 2% 
F15 STEARIC ACID OLEIC ACID 70:30 1:5 3% 2% 
F16 STEARIC ACID OLEIC ACID 70:30 1:7 1% 2% 
F17 STEARIC ACID OLEIC ACID 70:30 1:7 2% 2% 
F18 STEARIC ACID OLEIC ACID 70:30 1:7 3% 2% 
 
 
TABLE 2C:  COMPOSITION OF SIMVASTATIN NLC 
 
FORMULATION
CODE 
LIPID COMPOSITION 
SOLID LIPID : LIQUID LIPID 
RATIO 
DRUG -LIPID 
RAIO 
SURFACTANT 
CONCENTRATION 
SOLID 
LIPID 
LIQUID 
LIPID 
PHOSPOLIPON 
(% W/V) 
TWEEN-80 
(% W/V) 
F19 COMPRITOL GMO 70:30 1:3 1% 2% 
F20 COMPRITOL GMO 70:30 1:3 2% 2% 
F21 COMPRITOL GMO 70:30 1:3 3% 2% 
F22 COMPRITOL GMO 70:30 1:5 1% 2% 
F23 COMPRITOL GMO 70:30 1:5 2% 2% 
F24 COMPRITOL GMO 70:30 1:5 3% 2% 
F25 COMPRITOL GMO 70:30 1:7 1% 2% 
F26 COMPRITOL GMO 70:30 1:7 2% 2% 
F27 COMPRITOL GMO 70:30 1:7 3% 2% 
  
TABLE 3 
DRUG CONTENT OF SIMVASTATIN NLC 
  
 
S.NO 
 
 
FORMULATION CODE 
 
 
DRUG CONTENT (%)  ± 
SD 
1 F1 94.07±0.771 
2 F2 94.39±1.082 
3 F3 94.50±0.412 
4 F4 94.01±1.083 
5 F5 93.52±0.577 
6 F6 94.13±0.429 
7 F7 93.25±0.730 
8 F8 94.72±0.249 
9 F9 94.01±1.083 
10 F10 94.74±0.871 
11 F11 93.37±0.737 
12 F12 93.47±0.911 
13 F13 92.87±0.408 
14 F14 93.36±0.820 
15 F15 94.23±0.836 
16 F16 93.63±1.020 
17 F17 93.47±0.863 
18 F18 93.31±0.433 
19 F19 94.29±0.714 
20 F20 93.58±0.836 
21 F21 93.96±0.587 
22 F22 93.69±0.677 
23 F23 93.15±0.592 
24 F24 94.02±0.736 
25 F25 94.50±0.578 
26 F26 93.96±0.432 
27 F27 93.25±0.408 
 
n=3* 
 TABLE 4A: ENTRAPMENT EFFICIENCY OF SIMVASTATIN NLC 
CONTAINING GLYCERYL MONO STEARATE & CAPRYOL  
 
FORMULATION 
CODE 
LIPID 
(%) 
SURFACTANT 
% W/V 
ENTRAPMENT 
EFFICIENCY 
(%) ± SD 
F1 3 1 29.38±2.260 
F2 3 2 37.62±2.041 
F3 3 3 41.26±1.255 
F4 5 1 33.43±0.616 
F5 5 2 40.07±2.263 
F6 5 3 43.14±0.917 
F7 7 1 40.74±2.504 
F8 7 2 49.37±0.571 
F9 7 3 54.13±0.867 
 
n=3* 
 
 
 
 
 
 
 
 
 
TABLE 4B: ENTRAPMENT EFFICIENCY OF SIMVASTATIN NLC 
CONTAINING STEARIC ACID & OLEIC ACID  
 
 
FORMULATION 
CODE 
LIPID 
(%) 
SURFACTANT
% W/V 
ENTRAPMENT 
EFFICIENCY (%) ± 
SD 
F10 3 1 25.61±1.642 
F11 3 2 34.54±1.117 
F12 3 3 41.87±1.377 
F13 5 1 29.18±1.007 
F14 5 2 37.38±0.629 
F15 5 3 40.64±1.358 
F16 7 1 37.77±1.076 
F17 7 2 43.52±1.453 
F18 7 3 49.72±0.449 
 
n=3* 
 
 
 
 
 
 
 
 
 TABLE 4C: ENTRAPMENT EFFICIENCY OF SIMVASTATIN NLC 
CONTAINING COMPRITOL & GLYCERYL MONO OLEATE  
 
 
FORMULATION 
CODE 
LIPID 
(%) 
SURFACTANT
% W/V 
ENTRAPMENT 
EFFICIENCY (%) 
± SD 
F19 3 1 41.98±1.228 
F20 3 2 46.70±2.306 
F21 3 3 52.84±1.423 
F22 5 1 52.12±1.011 
F23 5 2 58.44±1.332 
F24 5 3 62.16±1.606 
F25 7 1 56.05±2.142 
F26 7 2 63.24±2.435 
F27 7 3 67.76±1.523 
 
n=3* 
 
 
 
 
 
 
  
TABLE 5A:  COMPARISON OF INVITRO RELEASE PROFILE OF SIMVASTATIN LOADED NLC CONTAINING    GLYCERYL MONO 
STEARATE & CAPRYOL LIPIDS 
 
TIME 
(HRS) 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
F1 
LIPID  
3% + 1% 
Phospolipon 
F2 
LIPID 
3% + 2% 
Phospolipon 
F3 
LIPID  
3% + 3% 
Phospolipon 
F4 
LIPID  
5% + 1% 
Phospolipon 
F5 
LIPID  
5% + 2% 
Phospolipon 
F6 
LIPID  
5% + 3% 
Phospolipon 
F7 
LIPID  
7% + 1% 
Phospolipon 
F8 
LIPID  
7% + 2% 
Phospolipon 
F9 
LIPID  
7% + 3% 
Phospolipon 
0.5 23.07±0.77 16.99±1.56 15.53±0.60 18.66±0.76 14.92±1.69 13.58±0.84 14.58±2.05 12.23±0.69 10.67±0.89 
1 29.27±1.28 23.01±1.63 21.29±0.86 24.38±0.71 21.05±2.12 19.47±0.68 20.93±2.29 18.28±0.78 16.03±1.28 
1.5 34.76±1.54 28.55±2.39 25.91±0.69 29.49±0.87 25.84±2.49 24.36±0.77 25.89±2.64 23.43±0.69 21.11±1.39 
2 39.63±1.58 32.80±3.63 30.58±0.63 34.69±0.91 30.89±2.92 29.18±1.02 30.73±2.37 28.36±0.56 26.01±1.40 
3 42.82±1.84 36.42±2.99 34.40±0.92 38.50±1.01 34.50±2.79 33.09±0.71 34.38±3.12 31.88±0.70 29.73±1.07 
4 45.97±1.99 40.52±3.09 37.65±0.67 42.34±1.12 37.74±2.05 36.66±0.62 38.74±2.82 35.55±0.71 33.59±0.90 
5 49.49±2.14 44.49±3.69 41.58±1.01 45.93±0.97 41.18±1.91 40.04±0.77 42.30±2.85 38.74±0.96 37.45±0.43 
6 53.09±1.74 47.72±3.06 45.51±1.19 49.67±0.67 44.82±2.41 43.38±0.82 45.67±3.13 42.02±1.14 40.71±0.19 
7 56.17±1.67 51.58±3.06 49.35±1.08 53.33±0.57 48.32±2.36 46.87±0.99 49.07±2.64 45.49±1.00 43.89±0.42 
8 59.22±0.61 56.15±2.24 53.11±1.19 56.97±0.74 51.63±2.65 50.22±1.18 53.11±3.27 48.95±1.01 47.28±0.49 
9 63.86±0.46 59.87±1.77 57.31±1.23 60.86±0.86 55.25±2.49 53.77±1.10 57.07±3.31 52.59±0.86 50.29±0.85 
10 67.41±0.50 64.07±1.83 60.75±0.69 64.61±0.87 59.29±2.37 57.46±0.78 60.69±3.43 56.11±0.76 53.62±1.01 
11 71.45±0.31 67.79±1.44 64.34±0.70 68.18±1.06 63.53±2.39 61.07±0.76 64.94±3.08 59.37±1.18 56.64±1.31 
12 75.81±1.43 71.05±1.96 67.84±0,61 71.99±0.96 67.75±2.52 64.72±0.86 68.62±3.15 62.72±1.36 59.79±1.09 
 
n=3* 
TABLE 5B:  COMPARISON OF INVITRO RELEASE PROFILE OF SIMVASTATIN  LOADED NLC CONTAINING  STEARIC ACID & 
OLEIC ACID LIPIDS 
 
 
 
TIME 
(HRS) 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
F10 
LIPID 
3% + 1% 
Phospolipon 
F11 
LIPID 
3% + 2% 
Phospolipon 
F12 
LIPID 
3% + 3% 
Phospolipon 
F13 
LIPID 
5% + 1% 
Phospolipon 
F14 
LIPID 
5% + 2% 
Phospolipon 
F15 
LIPID 
5% + 3% 
Phospolipon 
F16 
LIPID 
7% + 1% 
Phospolipon 
F17 
LIPID 
7% + 2% 
Phospolipon 
F18 
LIPID 
7% + 3% 
Phospolipon 
0.5 26.71(±)2.88 20.28(±)3.56 15.42(±)2.11 22.13(±)2.09 17.94±0.42 15.70(±)2.43 16.62(±)0.59 12.85(±)2.61 10.33(±)2.37 
1.0 32.79(±)3.36 26.41(±)3.24 21.44(±)1.87 27.99(±)2.20 23.93±0.51 21.78(±)2.63 22.66(±)0.59 18.85(±)2.39 16.14(±)2.16 
1.5 37.92(±)3.25 31.59(±)3.49 26.57(±)1.67 33.13(±)2.24 29.31±0.59 27.14(±)2.58 27.74(±)0.84 24.15(±)2.54 21.41(±)2.29 
2.0 43.16(±)3.23 36.76(±)3.53 31.59(±)1.71 38.09(±)2.19 34.57±0.81 32.21(±)2.67 32.63(±)0.97 29.08(±)2.56 26.32(±)2.32 
3.0 46.82(±)3.29 40.53(±)3.49 35.25(±)1.69 41.77(±)2.19 38.49±1.00 36.11(±)2.79 36.64(±)1.21 32.88(±)2.12 30.09(±)1.87 
4.0 50.52(±)3.41 44.45(±)3.73 39.34(±)1.88 45.69(±)2.03 42.10±0.92 39.75(±)3.07 40.35(±)1.46 36.73(±)2.13 33.91(±)1.88 
5.0 54.19(±)2.96 48.06(±)3.21 43.13(±)2.13 49.77(±)2.05 45.97±0.72 43.55(±)2.96 44.26(±)1.48 40.19(±)2.27 37.34(±)2.02 
6.0 58.12(±)3.04 51.38(±)3.02 46.78(±)1.94 53.88(±)2.10 49.94±0.72 47.54(±)2.97 48.20(±)0.78 44.18(±)2.18 41.30(±)1.92 
7.0 62.02(±)3.01 55.11(±)2.75 50.92(±)2.08 57.75(±)2.45 53.93±0.59 51.41(±)3.16 52.35(±)0.79 47.95(±)2.43 45.05(±)2.18 
8.0 65.52(±)3.12 58.87(±)2.48 54.98(±)2.13 61.54(±)2.40 57.97±0.76 55.36(±)3.09 56.21(±)0.56 51.85(±)2.58 48.51(±)1.72 
9.0 69.21(±)3.26 62.39(±)2.36 58.79(±)1.93 65.58(±)2.35 61.87±0.82 59.41(±)3.13 60.26(±)1.04 55.86(±)2.59 52.91(±)2.33 
10.0 73.04(±)2.85 65.99(±)2.27 62.54(±)1.95 69.55(±)2.22 65.75±0.66 63.26(±)3.40 64.43(±)1.64 59.57(±)2.62 56.59(±)2.35 
11.0 76.90(±)2.63 69.39(±)2.37 66.58(±)1.96 73.44(±)2.34 69.60±0.75 67.09(±)3.45 68.38(±)1.18 63.31(±)2.17 60.31(±)1.90 
12.0 80.35(±)2.24 72.72(±)2.12 69.83(±)1.95 77.25(±)2.45 73.43±0.59 70.85(±)2.89 72.28(±)1.31 66.75(±)1.95 63.64(±)1.56 
 
n=3* 
 
TABLE 5C:  COMPARISON OF  INVITRO RELEASE PROFILE OF SIMVASTATIN  LOADED NLC CONTAINING  COMPRITOL & 
GLYCERYL MONO OLEATE  LIPIDS 
 
 
 
TIME 
(HRS) 
CUMULATIVE  PERCENTAGE DRUG RELEASE ± SD 
F19 
LIPID  
3% + 1% 
Phospolipon 
F20 
LIPID  
3% + 2% 
Phospolipon 
F21 
LIPID 
3%+3% 
Phospolipon 
F22 
LIPID  
5% + 1% 
Phospolipon 
F23 
LIPID  
5% + 2% 
Phospolipon 
F24 
LIPID  
5% + 3% 
Phospolipon 
F25 
LIPID  
7% + 1% 
Phospolipon 
F26 
LIPID  
7% + 2% 
Phospolipon 
F27 
LIPID  
7% + 3% 
Phospolipon 
0.5 13.63±1.93 12.29±0.79 11.68±2.87 12.96±1.01 10.39±0.76 9.61±1.24 11.12±3.06 9.44±0.84 8.27±0.35 
1.0 19.63±1.87 17.50±0.77 16.66±3.13 18.23±1.03 15.91±0.85 14.90±1.41 16.37±3.29 14.68±0.85 13.38±0.35 
1.5 25.09±1.97 22.48±0.86 21.29±3.08 22.94±1.04 20.66±0.85 19.19±1.74 21.11±3.39 19.13±1.12 17.59±0.58 
2.0 30.03±1.99 27.29±1.36 25.69±3.03 27.69±0.79 25.28±0.70 23.46±2.14 25.85±3.42 23.45±1.37 21.68±0.43 
3.0 33.79±1.87 31.13±1.38 29.36±3.08 31.04±0.88 28.65±0.87 26.42±1.95 29.18±3.20 26.31±1.78 24.46±0.69 
4.0 37.69±1.96 34.68±1.24 33.11±3.13 34.36±0.72 32.01±0.81 29.76±2.37 32.43±3.28 29.64±1.94 27.39±0.53 
5.0 41.25±1.81 38.48±1.24 36.56±2.85 37.93±0.63 35.28±0.77 33.12±2.23 35.98±3.56 33.00±1.94 30.27±0.72 
6.0 45.05±1.85 42.26±1.43 40.04±2.78 41.65±0.73 38.64±0.66 36.90±2.15 39.57±3.24 36.45±1.77 33.64±0.81 
7.0 48.84±2.09 45.79±1.37 43.39±2.67 45.07±0.79 41.97±0.65 40.38±1.89 42.97±3.03 39.92±1.63 37.21±1.06 
8.0 52.88±2.02 49.80±1.29 46.87±2.28 48.46±0.73 45.28±0.66 43.45±2.49 46.34±2.47 43.33±1.75 40.69±0.84 
9.0 56.67±1.86 53.29±1.2 50.50±2.29 52.10±0.70 48.61±0.86 46.38±2.37 49.96±2.37 46.25±1.89 43.93±0.83 
10.0 60.51±1.97 56.98±1.05 53.77±2.19 55.45±0.92 51.86±0.96 49.78±2.17 53.45±1.87 49.54±1.63 47.19±0.86 
11.0 64.17±1.86 60.76±1.06 57.46±1.80 58.76±1.25 55.25±0.88 53.09±2.17 56.91±1.67 53.08±1.73 50.32±0.86 
12.0 67.82±1.86 64.06±1.06 61.29±1.74 62.49±1.09 58.56±0.86 56.61±2.09 60.63±1.85 56.59±1.64 53.81±0.91 
 
n=3* 
TABLE 6A:  RELEASE KINETICS OF SIMVASTATIN LOADED NLC CONTAINING  GLYCERYL MONOSTEARATE & CAPRYOL 
 
Formulation 
code 
Zero order First order Higuchi model 
Korsmeyer 
peppas Hixon-Crowell 
 
R2 
 
K0 
(h-1) 
 
R2 
 
K1 
(h-1) 
 
R2 
 
KH 
(h-1/2) 
 
R2 
 n 
 
R2 
 
KHC 
(h-1/3) 
F1 0.876 4.707 0.980 -0.038 0.987 17.56 0.988 0.353 0.985 -0.104 
F2 0.924 4.823 0.990 -0.036 0.992 18.73 0.993 0.433 0.992 -0.104 
F3 0.931 4.657 0.993 -0.033 0.993 18.19 0.994 0.448 0.993 -0.097 
F4 0.910 4.776 0.990 -0.036 0.994 18.38 0.994 0.411 0.991 -0.103 
F5 0.926 4.557 0.986 -0.032 0.989 17.77 0.992 0.448 0.987 -0.094 
F6 0.935 4.570 0.989 -0.031 0.992 18.25 0.988 0.523 0.986 -0.093 
F7 0.931 4.709 0.990 -0.034 0.992 18.47 0.994 0.462 0.990 -0.099 
F8 0.929 4.367 0.990 -0.029 0.993 17.25 0.992 0.484 0.986 -0.081 
F9 0.935 4.274 0.991 -0.027 0.996 17.08 0.994 0.518 0.987 -0.084 
 
TABLE 6B:  RELEASE KINETICS OF SIMVASTATIN LOADED NLC CONTAINING  STEARIC ACID & OLEIC ACID  LIPIDS  
 
Formulation 
code 
Zero order First order Higuchi model 
Korsmeyer 
peppas Hixon-Crowell 
 
R2 
 
K0 
(h-1) 
 
R2 
 
K1 
(h-1) 
 
R2 
 
KH 
(h-1/2) 
 
R2 
 n 
 
R2 
 
KHC 
(h-1/3) 
F10 0.865 4.994 0.987 -0.045 0.993 18.48 0.991 0.337 0.991 -0.118 
F11 0.900 4.939 0.988 -0.040 0.993 18.86 0.994 0.394 0.991 -0.110 
F12 0.930 4.823 0.992 -0.036 0.993 18.90 0.994 0.458 0.992 -0.102 
F13 0.901 5.026 0.988 -0.042 0.993 19.10 0.992 0.383 0.992 -0.114 
F14 0.919 4.942 0.990 -0.038 0.993 19.15 0.993 0.428 0.991 -0.108 
F15 0.928 4.858 0.990 -0.036 0.993 19.01 0.994 0.454 0.991 -0.104 
F16 0.929 4.926 0.989 -0.038 0.992 19.21 0.993 0.445 0.992 -0.107 
F17 0.939 4.702 0.992 -0.033 0.993 18.63 0.994 0.494 0.991 -0.097 
F18 0.950 4.598 0.992 -0.031 0.993 18.45 0.992 0.541 0.991 -0.093 
 
TABLE 6C:  RELEASE KINETICS OF SIMVASTATIN LOADED NLC CONTAINING  COMPRITOL & GLYCERYL MONO OLEATE  
LIPIDS 
Formulation 
code 
Zero order First order Higuchi model 
Korsmeyer 
peppas Hixon-Crowell 
 
R2 
 
K0 
(h-1) 
 
R2 
 
K1 
(h-1) 
 
R2 
 
KH 
(h-1/2) 
 
R2 
 n 
 
R2 
 
KHC 
(h-1/3) 
F19 0.935 4.730 0.991 -0.034 0.993 18.67 0.994 0.481 0.991 -0.099 
F20 0.944 4.542 0.993 -0.031 0.994 18.05 0.995 0.501 0.992 -0.092 
F21 0.944 4.311 0.992 -0.028 0.993 17.13 0.995 0.501 0.991 -0.085 
F22 0.935 4.333 0.992 -0.029 0.993 17.08 0.994 0.474 0.991 -0.086 
F23 0.940 4.146 0.991 -0.026 0.993 16.51 0.992 0.513 0.993 -0.097 
F24 0.949 4.044 0.993 -0.025 0.993 16.17 0.993 0.527 0.991 -0.077 
F25 0.944 4.276 0.991 -0.028 0.992 17.01 0.993 0.507 0.990 -0.084 
F26 0.950 4.040 0.992 -0.023 0.992 16.17 0.992 0.531 0.990 -0.077 
F27 0.956 3.882 0.854 -0.056 0.990 15.60 0.990 0.551 0.990 -0.073 
  
TABLE 7A: PARTICLE SIZE OF SIMVASTATIN NLC CONTAINING 
GMS-CAPRYOL  
FORMULATION 
CODE LIPID (%) 
MEAN 
DIAMETER 
(nm) 
PDI 
F3 3% 118 0.257 
F6 5% 54.01 0.138 
F9 7% 108.1 0.313 
 
 
TABLE 7B: PARTICLE SIZE OF SIMVASTATIN NLC CONTAINING 
STEARIC ACID- OLEIC ACID  
FORMULATION 
CODE LIPID (%) 
MEAN 
DIAMETER 
(nm) 
PDI 
F12 3% 53 0.295 
F15 5% 14.06 0.347 
F18 7% 44.05 0.402 
 
 
TABLE 7C: PARTICLE SIZE OF SIMVASTATIN NLC CONTAINING 
COMPRITOL-GMO  
FORMULATION 
CODE LIPID (%) 
MEAN 
DIAMETER 
(nm) 
PDI 
F21 3% 217.8 0.401 
F24 5% 94.43 0.274 
F27 7% 235.2 0.258 
 
 
TABLE 8:  ZETA POTENTIAL OF SIMVASTATIN NLC CONTAINING 
PHOSPHOLIPON 90G - 3% AS SURFACTAN 
   S. 
NO FORMULATION CODE 
ZETA POTENTIAL 
(mV) 
1 F3 -18.2 
2 F6 -21.7 
3 F9 -14.2 
4 F12 -11.63 
5 F15 -13.6 
6 F18 -16.2 
7 F21 -23.4 
8 F24 -19.2 
9 F27 -15.6 
 
 
TABLE 9:  COMPOSITION OF SIMVASTATIN  HYDROGEL 
 
 
 
SL. 
NO INGREDIENTS PLAIN GEL 
 
NLC Based HG 
1. Chitosan 2g 2g 
2. Acetic Acid 1% 1% 
3. Glycerine 1.5 ml 1.5 ml 
4. Water 50 ml 50 ml 
5. Drug  300 mg 25 ml 
 TABLE 10: APPEARANCE AND pH OF FORMULATIONS 
 
 
n=3* 
 
 
TABLE 11:  DRUG CONTENT OF HYDROGEL FORMULATION 
 
S.NO FORMULATION % DRUG CONTENT 
1 NLC Based HG 96.51±0.74 
2 Plain HG 97.71±0.43 
 
  n=3* 
 
 
 
FORMULATIONS 
 
 
APPEARANCE 
pH 
at 0 day 
pH 
at 15 th 
day 
pH 
at 30 th 
day 
NLC Based HG Yellow 5.3 5.2 5.2 
Plain HG Yellow 5.2 5.2 5.2 
 TABLE 12:  TEXTURE ANALYSIS OF GEL FORMULATIONS 
 
Gel Batch Code Firmness (Kg) 
Cohesiveness 
(Kg.sec) 
Consistency (Kg) 
Index of viscosity 
(Kg.sec) 
Plain HG 0.166±0.009 1.246±0.035 0.077± 0.006 0.404±0.050 
NLC Based HG 0.069±0.003 0.629±0.031 0.042±0.003 0.268±0.014 
NLC (F15) 0.010±0.001 0.108±0.015 0.005±0.000 0.002±0.000 
 
n=3* 
 
  
TABLE 13: EXVIVO SKIN PERMEATION STUDY 
TIME IN 
HOURS 
CUMULATIVE PERCENTAGE OF DRUG RELEASED 
NLC (F15) NLC BASED HG (NG) PLAIN HG (PG) 
0.5 15.58±1.58 11.79±1.11 4.63±0.83 
1 21.23±1.09 17.54±1.05 7.82±0.77 
1.5 26.21±1.14 22.74±1.02 11.01±0.58 
2 31.01±1.07 27.44±1.02 14.53±1.17 
3 34.31±1.16 31.18±0.67 17.21±1.93 
4 38.28±1.40 34.54±0.84 19.67±1.09 
5 41.52±1.46 37.83±0.67 23.69±1.42 
6 44.82±1.14 41.41±0.68 27.05±1.42 
7 48.45±1.36 44.98±0.69 30.01±1.02 
8 52.03±1.26 48.34±0.76 33.19±0.68 
9 55.27±1.17 51.69±0.79 36.83±0.84 
10 58.57±0.98 54.99±0.76 39.96±0.76 
11 61.81±1.30 58.23±0.42 43.14±0.63 
12 64.54±1.07 61.08±0.25 46.66±1.02 
n=3* 
 
TABLE 14: DRUG DEPOSITION STUDY 
FORMULATION 
% DRUG REMAINED 
ON SKIN AFTER 12 
HOUR 
% DRUG RETAINED 
INTO SKIN AFTER 12 
HOUR 
NLC (F15) 15.01±0.75 17.62±0.75 
NLC BASED HG (NG) 12.56±0.59 23.44±1.48 
PLAIN HG (PG) 41.11±1.34 9.13±0.49 
n=3* 
TABLE 15:  COMPARISION OF EX-VIVO  RELEASE KINETICS PROFILES 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGUCHI MODEL HIXSON-CROWELL 
KORSMEYER-
PEPPAS 
R2 KO(h-1) 
R2 K1(h-1) R2 KH h(-1/2) R2 KHC(h-1/3) R2 n value 
NLC (F 15) 0.971 3.911 0.993 -0.030 0.995 17.03 0.989 -0.089 0.995 0.432 
NLC Based HG 0.970 3.914 0.992 -0.028 0.994 17.05 0.987 -0.085 0.993 0.491 
Plain HG 0.993 3.465 0.995 -0.020 0.986 14.85 0.996 -0.066 0.995 0.700 
 
 
TABLE 16: COMPARISION OF PERCENTAGE WOUND CONTRACTION OF DIFFERENT GROUPS 
S.No Day of Observation 
Wound Contraction (%) 
Control Plain HG NLC Based HG 
2 4 26.80±0.60% 41.34±1.13% 48.29±0.69% 
3 7 48.54±1.59% 73.49±1.16% 81.94±1.16% 
4 10 62.74±1.37% 84.71±0.62% 94.96±0.35% 
5 12 78.69±1.60% 96.42±1.39% 100%*** 
n=6* 
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FIGURE 1A:  DETERMINATION OF λmax OF SIMVASTATIN  IN  
SALINE PHOSPHATE BUFFER pH 7.4 CONTAINING 0.15% SDS 
 
FIGURE 1B :  CALIBRATION CURVE OF SIMVASTATIN  USING  
PHOSPHATE BUFFER PH 7.4 CONTAINING 0.15% SDS 
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FIGURE 2A:  FT-IR SPECTRA OF SIMVASTATIN 
 
 
FIGURE 2B:  FT-IR SPECTRA OF GLYCERYL MONO STEARATE 
 
FIGURE 2C:  FT-IR SPECTRA OF SREARIC ACID 
 
 
FIGURE 2D:  FT-IR SPECTRA OF GLYCERYL BEHENATE 
FIGURE 2E:  FT-IR SPECTRA OF PHOSPHOLIPON 90G 
 
 
FIGURE 2F  FT-IR SPECTRA OF CHITOSAN 
 
FIGURE 2G:  FT-IR SPECTRA OF PHYSICAL MIXURE OF SIMVASTATIN + 
GLYCERYL MONO STEARATE + CHITOSAN 
 
 
FIGURE 2H:  FT-IR SPECTRA OF PHYSICAL MIXURE OF SIMVASTATIN + 
STEARIC ACID + CHITOSAN 
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FIGURE 4A  COMPARISON OF INVITRO RELEASE PROFILE OF SIMVASTATIN 
LOADED NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL 
MONOSTEARATE AND CAPRYOL LIPIDS 
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FIGURE 4B:  COMPARISON OF INVITRO RELEASE PROFILE OF SIMVASTATIN 
LOADED NANOSTRUCTURED LIPID CARRIES CONTAINING STEARIC ACID AND 
OLEIC ACID LIPIDS 
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FIGURE 4C:  COMPARISON OF INVITRO RELEASE PROFILE OF SIMVASTATIN 
LOADED NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL 
BEHENATE AND GLYCERYL MONO OLEATE LIPIDS 
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FIGURE 5A COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF  
NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL MONOSTEARATE 
AND CAPRYOL LIPIDS 
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FIGURE 5B:  COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF  
NANOSTRUCTURED LIPID CARRIES CONTAINING STEARIC AID  AND OLEIC 
ACID  LIPIDS 
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FIGURE 5C:  COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF  
NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL BEHENATE AND 
GLYCERYL MONO OLEATE LIPIDS 
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FIGURE 5D:   COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF  
NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL MONOSTEARATE 
AND CAPRYOL LIPIDS 
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FIGURE 5E:  COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF  
NANOSTRUCTURED LIPID CARRIES CONTAINING STEARIC ACID  AND OLEIC 
ACID LIPIDS 
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FIGURE 5F:   COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF  
NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL BEHENATE AND 
GLYCERYL MONO OLEATE LIPIDS 
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FIGURE 5G:   COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS 
OF  NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL 
MONOSTEARATE AND CAPRYOL 
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FIGURE 5H:   COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS 
OF  NANOSTRUCTURED LIPID CARRIES CONTAINING STEARIC ACID AND 
OLEIC ACID LIPIDS 
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FIGURE 5I:   COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS 
OF  NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL BEHENATE 
AND GLYCERYL MONO OLEATE LIPIDS 
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FIGURE 5J: COMPARISON OF INVITRO HIXSON-CROWELL  MODEL RELEASE 
KINETICS OF NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL 
MONOSTEARATE AND CAPRYOL 
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FIGURE 5K:   COMPARISON OF INVITRO HIXSON-CROWELL  MODEL RELEASE 
KINETICS OF NANOSTRUCTURED LIPID CARRIES CONTAINING STEARIC ACID 
AND OLEIC ACID LIPIDS 
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FIGURE 5L:   COMPARISON OF INVITRO HIXSON-CROWELL  MODEL RELEASE 
KINETICS OF NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL 
BEHENATE AND GLYCERYL MONO OLEATE LIPIDS 
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FIGURE 5M:   COMPARISON OF INVITRO KORSMEYER  PEPPAS MODEL 
RELEASE KINETICS OF NANOSTRUCTURED LIPID CARRIES CONTAINING 
GLYCERYL MONOSTEARATE AND CAPRYOL 
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FIGURE 5N:   COMPARISON OF INVITRO KORSMEYER  PEPPAS MODEL 
RELEASE KINETICS OF  NANOSTRUCTURED LIPID CARRIERS CONTAINING 
STEARIC ACID AND OLEIC ACID LIPIDS 
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FIGURE 5O:   COMPARISON OF INVITRO KORSMEYER  PEPPAS MODEL 
RELEASE NANOSTRUCTURED LIPID CARRIES CONTAINING GLYCERYL 
BEHENATE AND GLYCERYL MONO OLEATE LIPIDS 
  
        
 
FIGURE 6A:  PARTICLE SIZE DISTRIBUTION CURVE OF FORMULATIONS 
F3, F6 AND F9 
 
   
 
         FIGURE 6B:  PARTICLE SIZE DISTRIBUTION CURVE OF 
FORMULATIONS F12, F15 AND F18  
  
   
 
FIGURE 6C:  PARTICLE SIZE DISTRIBUTION CURVE OF FORMULATIONS 
F21, F24 AND F27 
  
 
 
 FIGURE 7 A   ZETA POTENTIAL CURVE OF FORMULATION F3, F6 AND F9 
  
 
 FIGURE 7B:   ZETA POTENTIAL CURVE OF FORMULATION F12, F15 AND F18 
 
  
 
FIGURE 7C:   ZETA POTENTIAL CURVE OF FORMULATION F21, F24 & F27  
 
  
 
FIGURE 8:  FT-IR SPECTRA OF BEST FORMULATION (F15) 
 
 
FIGURE 9: SCANNING ELECTRON MICROSCOPY  OF BEST 
FORMULATION F15 
 
 
FIGURE 10A: TEXTURE ANALYSIS OF PLAIN HYDROGEL 
 
 
FIGURE 10B: TEXTURE ANALYSIS OF NLC BASED HYDROGEL 
 
 
FIGURE 10C: TEXTURE ANALYSIS OF BEST NLC FORMULATION (F15) 
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FIGURE 11: COMPARISION OF EX-VIVO PERMEATION OF NLC, NLC 
BASED HYDROGEL & PLAIN HYDROGEL THROUGH EXCISED RAT SKIN  
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FIGURE 12A:  COMPARISON OF EXVIVO ZERO ORDER RELEASE KINETICS OF  
OF NLC, NLC BASED HYDROGEL & PLAIN HYDROGEL  
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FIGURE 12B:  COMPARISON OF EXVIVO FIRST ORDER RELEASE KINETICS OF  
OF NLC, NLC BASED HYDROGEL & PLAIN HYDROGEL  
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FIGURE 12A:  COMPARISON OF EXVIVO HIGUCHI MODEL  RELEASE KINETICS 
OF  OF NLC, NLC BASED HYDROGEL & PLAIN HYDROGEL  
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FIGURE 12A:  COMPARISON OF EXVIVO HIXON CROWEL  RELEASE KINETICS 
OF  OF NLC, NLC BASED HYDROGEL & PLAIN HYDROGEL  
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FIGURE 12A:  COMPARISON OF EXVIVO KORS MEYER PEPPAS MODEL 
RELEASE KINETICS OF  OF NLC, NLC BASED HYDROGEL & PLAIN 
HYDROGEL 
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CHAPTER - XI 
SUMMARY AND CONCLUSION 
 The purpose of this research was to develop a simvastatin  
loadednanostuctured lipid carrier based hydrogels as a potential 
dermatological formulation for diabetic wound healing with enhanced 
permeation, sustained drug release and enhanced drug release at the site of 
action. 
 Infrared spectroscopic studies confirmed that there was no interaction between 
drug, lipids and excipients. 
 Hot homogenization followed by ultrasonication were employed to produce 
NLCs using a range of solid lipids (stearic acid, Glyceryl mono stearate and 
compritol) , liquid lipids (capryol, oleic acid and GMO) and surfactants 
(Tween 80, phospolipon 90G). 
 The entrapment efficiency increased with increasing the concentrationof  
lipids and phospholipon 90G and the formulations containing Phospholipon 
90G at 3% showed higher entrapment irrespective of the lipids composition. 
 The mean particle  size  of  simvastatin loadednanostructured lipid 
carrierformulations  F1-F27 showed  a  suitable  particle  size  in  the range  of  
14.06  nm-235.2 nm and thepolydispersity  index were less  than  0.5,  
whichindicated  a  relative  homogenous  dispersion. 
  The  zeta  potential  of  simvastatin loaded  NLC showed  a  negative  surface  
charge(-11.63 mV to -23.4 mV)which revealed that the prepared NLC have 
sufficient charge and mobility to inhibit aggregation of particles. 
 Theinvitrorelease studies displayed a similar biphasic drug release pattern with 
a burst release within 2 hours followed by sustained release at 12 hours. 
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 The best formulation  F15 containing stearic acid and oleic acid  showed the 
spherical shaped particles in the  size of 14.06 nm , PDI (0.347) and zeta 
potential (-13.6 mV) with acceptable EE of 40.64% and invitro release of 
70.85% after 12 hrs and which is successfully incorporated into chitosan HG. 
 Texture Anayser TA- XT Plus confirmed the desired  properties of firmness, 
adhesiveness and viscosity of prepared NLC based HG. 
 The ex vivo release studies and drug deposition studies indicated that the 
prolonged drug release and better penetration capacity of NLC based HG as 
compared to NLC dispersion and plain HG. Chitosan was also playing an 
important role for the prolong release of simvastatin up to 12 hrs.  
 Invitro release kinetics revealed that the classical Fickian diffusion was the 
release mechanism for NLC dispersion and anomalous non-Fickian for both 
NLC based HG and plain HG. 
 The results of the invivo diabetic wound healing study indicate that 
simvastatin loaded NLC based HG promote the healing in diabetic wounds 
with faster and higher wound contraction rate as compared to NLC dispersion 
and plain HG. Skin irritation study was also shown that no irritation on skin. 
Hence, it wasconcludedthat the hot homogenization  was a useful method for the 
successfulincorporation of simvastatin inNanostructured lipid carrier with higher EE, 
sustained drug release and smaller particle size.The result indicates that NLC Based 
HG enhanced the permeation, sustained the drug release and enhanced the drug 
release at the site of action due to submicron size of lipid nanoparticles and gel matrix 
of chitosan HG. Thus the NLC based HG can be used as novel drug delivery carrier 
for skin targeting of simvastatin for its diabetic wound healing action. 
  
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
                                                                                                                           References 
 
REFERENCES 
Abdul HasanSathali A., Ekambaram P., Priyanka K., 2011.  Solid Lipid 
Nanoparticles: A review, Sci. Revs. Chem. Commun:.,  2(1),  80-102. 
Autio, K., Kuuva, T., Roininen, K., &Lahteenmaki, L.  2003. Rheological properties, 
microstructure and sensory perception of high-amylose starch-pectin mixed gels. Journal 
of Texture Studies, 33, 473-486. 
Bao P., Kodra A., Tomic-Canic M., Golinko M.S., Ehrlich H.P. and Berm H., 2009. 
The role of vascular endothelial growth factor in wound healing. Journal of 
SurgicalResearch 153, 347-358. 
Bhaskar K., Krishna Mohan C., Lingam M., Jagan Mohan S., Venkateswarlu V., 
MadhusudanRao Y., Anbu J., Ravichandran V., 2009. Development of SLN and NLC 
enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo 
characteristics, Drug Dev. Ind. Pharm. 35 (2009) 98–113. 
Boateng J.S., Matthews K.H., Stevens H.N.E.  And Eccleston G.M., 2008. Wound 
healing dressings and drug delivery systems: A review. Journal of 
PharmaceuticalSciences 97, 2892-2923. 
Brouet A, Sonveaux R, Chantal D., 2001. HSP 90 &caveolin are key targets for the 
proangigiogenic nitric oxidemediated effects of statins. Cir Res, 2001; 89: 866-73. 
Chen J, Zhang ZG, Yi Li., 2006. Statins induceangiogenesis, neurogenesis & 
synaptogenesis after stroke. Ann Neurol,2006;16:313-25. 
Cherry GW, Margaret A. Huges M, Fergason, David J. In: Moitis P J, Wood W C., 
Wound healing 2nd ed. NewYork. Alison,Langston, :136-42. 
                                                                                                                           References 
 
Falanga  V., 2003. The chronic wound: impaired healing and solutions in the context of 
wound bed preparation. Blood Cells, Molecules, and Diseases, 32, 88-94. 
Feron O., Chantal D., Desager J., et al., 2001.,Hydroxymethylglutazylcoenzyme 
reductase inhibition promotesendothelial nitric oxide synthase activation through 
adecrease in caveolin abundance. Circ, 2001;103: 113-18.  
Fonder M.A., Lazarus G.S., Cowan D.A., Aronson-Cook B., Kohli A.R.  
andMamelak A.J. ,2008.Treating the chronic wound: A practical approach to the care of 
non-healing wounds and wound care dressings.Journal of the American Academy 
ofDermatology 58, 185-206. 
Goossens A., and  Cleenewerck  M-B., 2010. New wound dressing: classification, 
tolerance. European Journal of Dermatology 20, 24-26. 
Hazimah Abu Hassan., Chooyuenmay., 2011. An improved method for the 
preparations of nanostructured lipid carriers containing heat-sensitive bioactives, 
Biointerfaces 87 (2011) 180-186. 
Helms R. A., Quan D. J., Herfindal E. T., Gourley D. R., 2006. Textbook of 
Therapeutics, Drug and Disease Management, 7th Edition, Lippincott Williams & 
Wilkins, Philadelphia. 
Huang S., and Fu X., 2010.Naturally derived materials-based cell and drug delivery 
systems in skin regeneration.Journal of Controlled Release 142,149-159. 
Izadi K., Ganchi P., 2005.Chronic wounds.Clin Plastic Surg, 32, 209-222. 
Jagur-Grodzinski J., 2009. Polymeric gels and hydrogels for biomedical and 
pharmaceutical application.Polymers for Advanced Technology 21, 27-47. 
                                                                                                                           References 
 
Jones D.S., 1999. Dynamic mechanical analysis of polymeric systems of pharmaceutical 
and biomedical significance, Int. J. Pharm. 179 (1999) 167–178. 
Jones D.S., Woolfson A.D., Brown  A.F., 1997.Textural Analysis, Flow rheometry of 
novel, bioadhesive antimicrobial oral gels, Pharm. Res. 14 (1997) 450–457. 
Jun Asai.,  HideyaTakenaka., Satoshi Hirakawa., 2012. Topical simvastatin 
accelerates wound healing in diabetes by enhancing angiogenesis and 
lymphangiogenesis, The American Journal of Pathology, Volume 181, Issue 6. 
Keck C.M.,  Kovacevic A.,  Savic S.,  Vuleta G.,  Muller R. Hin., 2011.Polyhydroxy 
surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, 
physical stability and particle matrix structure,  Int.J. of  pharm., 406,  163-172. 
Keong L. C., Halim A. S. , 2009. In vitro models in biocompatibility assessment for 
biomedical grade chitosan derivatives in wound management. International Journal of 
Molecular Sciences 10,1300-1313  
Keong L. C., Halim A. S., 2009. In vitro models in biocompatibility assessment for 
biomedical grade chitosan derivatives in wound management. International Journal of 
Molecular Sciences 10, 1300-1313. 
Kopecek J., 2009.Hydrogels from soft contact lenses and implants to self-assembled 
nanomaterials.Journal of Polymer Science Part A: Polymer Chemistry 47, 5929-5946.  
Kopeček J., 2009.Hydrogels from soft contact lenses and implants to self-assembled 
nanomaterials.Journal of Polymer Science Part A: Polymer Chemistry 47, 5929-5946  
Kopecek J., and Yang J. ,2007.Review, Hydrogels as smart biomaterials.Polymer 
International 56, 1078-1098. 
                                                                                                                           References 
 
Kureshi Y, Luo Z, Shiojima I., 2000. The HMG-COAreductase inhibitor activates the 
protein kinase AKT &promotes angiogenesis in normocholesterolemic animals.Nat Med, 
2000; 6: 1004-10. 
Kwak B., Mulhaupt F., Myit S., 2000. Statins as a newly recognized type of 
immunomodulator.Nat Med.; 6, 1399–402. 
Laufs U, Liao JK., 1998. Post-transcriptional regulation of endothelial nitric oxide 
synthase mRNA stability by Rho GTPase.J Biol Chem.273, 24266–71. 
Laufs U., Gertz K., Huang P., 2000. Atorvastatinupregulates type III nitric oxide 
synthase in thrombocytes,decreases platelet activation & protects from cerebralischemia 
in normocholesterolemic mice. Stroke, 2000;31:2442. 
Lee PC, Neil SP, Gcoynne A., 1999.Impaired woundhealing & angiogenesis in eNOS- 
debricient mice.Am J Physiol Heart Circ, 1999; 277: 1600-8. 
Li J, Zhang YP, KitsnetRS., 2003. Angiogenesis in woundhealing:Angiogenic growth 
factors & the extracellularmatrix. J Micro Sc Res Tech, 2003; 60 (1):107-14. 
Lippacher A., Muller R.H., Mader K., 2001.Preparation of semisolid drug carriers for 
topical application based on solid lipid nanoparticles, Int. J. Pharm. 214 (2001) 9–12. 
Loo Chew Hung., MahiranBasri., Bimo A. Tejo., Rosnah Ismail., Harrison Lau Lik 
Nang 
Mahley W., Robert &Bersot TP., .Drug therapy forhypercholesterolemia & 
dyslipidemia. In: JoelGH., Lee EL., Alfred GG., 2001. The Pharmacological basis of 
therapeutics,10th ed. New York: McGraw Hill publication, 2001:971-1002. 
Marreto R.N ., Souza L.G ., Silva E.J .,  Martins A.L.L .,  Mota M.F.,  Braga R.C ., 
Lima E.M ., Valadares M.C ., Taveira S.F., 2011.  Development of topotecan loaded 
                                                                                                                           References 
 
lipid nanoparticles for chemical stabilization and prolonged release,  Eur. .J 
Pharm.andBiopharm , 79,  189-196 
Mason JC., 2003.,Statins & their role in vascularprotection. Clin Sci. 2003;105: 251-66. 
Mehdi H., Luise Brennan M., Ronnier J., 2003.Statins promote potent systemic 
antioxidant effects throughspecific inflammatory pathways.Circ, 2003; 108: 426-31. 
Merx MW, Liehn EA, Janssens U, Lütticken R, Schrader J, Hanrath P, Weber C., 
2004. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a 
murine model of sepsis. Circulation.109, 2560-5. 
Müller  R.H., Mäder  K., Gohla, S., 2000. Solid lipid nanoparticles (SLN) for 
controlled drug delivery A review of the state of art, Eur. J. Pharm. Biopharm. 50, 161-
177. 
Müller  R.H., Radtke  M., Wissing  S.A.,2002., Solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Adv. 
Drug Deliv.Rev. 54, S131-S155. 
Müller  R.H., Radtke M., Wissing  S.A., 2004. Solid lipid nanoparticles and 
nanostructured lipid carriers, in: Encyclopedia of nanoscience and nanotechnology, H.S. 
Nalwa, Ed., American Scientific Publishers. p. 43-56. 
Müller  R.H., Wissing  S.A., 2003.Lipopearls for topical delivery of active compounds 
and controlled release, in: Modified-release drug delivery systems, M.J. Rathbone, 
Hadgraft, J., Roberts, M. S., Ed., Marcel Dekker Inc.: New York, Basel, Hong-Kong. p. 
571- 587. 
                                                                                                                           References 
 
Müller R.H., Mehnert  W., Souto  E.B., 2005. Solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) for dermal delivery, in: Percutaneous Absorption, L. 
Bronaugh, Ed., Marcel Dekker, Inc.: New York, Basel, Hong-Kong. p. 719-738. 
Müller R.H., Radtke  M., Wissing  S.A., 2002. Solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Adv. 
Drug Deliv.Rev. 54, S131-S155. 
Müller R.H., Radtke M., Wissing S.A., 2002.Nanostructured lipid matrices for 
improved microencapsulation of drugs, Int. J. Pharm. 242, 121-128. 
Müller R.H., Radtke M., Wissing S.A., 2004.Solid lipid nanoparticles and 
nanostructured lipid carriers, in: Encyclopedia of nanoscience and nanotechnology, H.S. 
Nalwa, Ed., American Scientific Publishers. p. 43-56. 
Müller R.H., Radtke, M., Wissing S.A., 2002.Nanostructured lipid matrices for 
improved microencapsulation of drugs, Int. J. Pharm. 242, 121-128. 
Naidu BV., Woolley SM., Farivar AS., Thomas R., Fraga C., Mulligan MS., 2003.  
Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J 
ThoracCardiovasc Surg. 126, 482-9. 
Okan G., Rendon MI., 2011. The Effects of A High Glycerin Content Hydrogel 
Premolded Mask Dressing on Post-Laser Resurfacing Wounds. J Cosmet Laser Ther 
2011; Aug; 13(4):162-5.  
Pallavi V.,  Pople, Kamalinder K.,  Singh., 2006. Development and Evaluation of 
Topical Formulation Containing Solid Lipid Nanoparticles of Vitamin A. AAPS 
PharmSciTech., 7(4): 91. (2006). 
                                                                                                                           References 
 
Pruefer D, Makowski J, Schnell M.,2003. Simvastatin inhibits inflammatory properties 
of Staphylococcus aureus alpha toxin. Circulation.106, 2104–2110. 
Rahul Nair., Vishnu Priya K., ArunKumar  K.S.,  BadivaddinT.Md.,  Sevukarajan 
M.,2011. Formulation and evaluation of solid lipid nanoparticles of Water Soluble Drug: 
Isoniazid ,J.Pharm. Sci. & Res. 3(5), 1256-1264. 
Rhett J. M., Ghatnekar G. S., Palatinus, J. A., OQuinn M.,  Yost  M. J., Gourdie 
R. G., 2008. Novel therapies for scar reduction and regenerative healing of skin wounds. 
Trends inBiotechnology, 26, 173-180. 
Ritger P.L., Peppas N.A., 1987.  A simple equation for description of solute release II. 
Fickian and anomalous release from swellable devices, J. Control. Release 5 (1987) 37–
42. 
Ritger P.L., Peppas N.A., 1987. A simple equation for description of solute release I. 
Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, 
cylinders or discs, J. Control. Release 5 (1987) 23–36. 
Sawant K K., Parmar B., Mandal S., Petkar K C., Patel L D., 2011.Valsartan  loaded  
solid lipid nanopartcles: Development, Characterization, and Invitro and Ex  vivo 
evaluation, Int. J of Pharm. Sci. and Nanotech., 4(3), 1483-1490. 
Schubert V., 1997.Measuring the erea of chronic ulcers for consistent documentation in 
clinical practice.Wounds, 9, 153- 159. 
Senthilanathan B.,  AnushaRupenagunta., Somasundaram I.,  Ravichandiran  V.,  
Kausalya J.,  Joseprakash D.,  2011.  Effect of Cholostrol and Surfactant Concentration 
on Solid Lipid Nanosuspension of Ropinirole Hydrochloride,  J.  of  Pharm. Res.,  4( 6), 
1606-1609. 
                                                                                                                           References 
 
Serra L., Doménech J., Peppas N.A., 2009.Engineering design and molecular dynamics 
of mucoadhesive drug delivery systems as targeting agents, Eur. J. Pharm. Biopharm. 71 
(2009) 519–528. 
Shailesh S. Chalikwar.,  Veena S. Belgamwar.,  Vivek R. Talele.,  Sanjay J. Surana., 
Mrunal U. Patil.,  2012  Formulation and evaluation of Nimodipine-loaded solid lipid 
nanoparticles delivered via lymphatic  Transport system,  Colloids and Surfaces  B: 
Biointerfaceacesrt system , 97,  109-116. 
Shaw T. J., Martin P., 2009. Wound repair at a glance. Journal of Cell Science 122, 
3209-3213 Muzzarelli, R. A. A., 2008.Chitins and chitosans for the repair of wounded 
skin, nerve, cartilage and bone.Carbohydrate Polymers, 76, 167-182. 
Siekmann  B., Westesen  K., 1998. Submicron lipid suspensions (Solid lipid 
nanoparticles) versus lipid nanoemulsions: similarities and differences, in: Submicron 
emulsions in drug targeting and delivery, S. Benita, Ed., Harwood Academic Publishers: 
Amsterdam, p. 205-218. 
Singla N., Gupta G.D., Kohli K., Singla A.K., 2009. A Discriminatory and Biorelevant 
Dissolution Test Method for Simvastatin Drug Products, 
SurajitDas ., WaiKiong Ng.,  Reginald B.H. Tan., 2012.  Are nanostructured lipid 
carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, 
characterization and comparative evaluations of clotrimazole-loaded SLNs and NLCs 
?Eur. J. Pharm., 47,  139-151. 
Suvakanta Dash., PadalaNarasimha Murthy., LilakantaNath., 
PrasantaChowdhury., 2010. Kinetic Modelling on drug release from controlled drug 
delivery systems, Acta.Poloniac.Pharm, 67(3)217-223. 
                                                                                                                           References 
 
Tabata Y., 2009.Biomaterial technology for tissue engineering applications, Journal of 
the Royal Society, Interface 6, S311-S324. 
Tandon V., Bano G., Khajuria V., 2005., Pleiotropiceffects of statins. Ind J Pharmacol, 
2005;37: 77-85. 
Urbich C., Dernbach E., Zeiher AM., Diemmek D., 2002.Double edged role of statins 
in angiogenesis signaling. Circ Res, 2002; 90 (6): 737-44. 
Vaneau M., Chaby G., Guillot B., Martel P., Senet P., Teot L.  andChosidow  O., 
2007.Consensus panel recommendations for chronic and acute wound dressings.Archives 
in Dermatolology143, 1291-1294. 
Vaneau M., Chaby G., Guillot B., Martel P., Senet P., Teot L., and Chosidow 
O.,2007.Consensus panel recommendations for chronic and acute wound 
dressings.Archives in Dermatolology143, 1291-1294. 
Weis M, Heeshan C, Glassbord AS, Cooke JP., 2002. Statinshave biphasic effects on 
angiogenesis.Circulation, 2002;105: 739-45. 
Wissing S.A., Kayser  O., Müller  R.H.,(2004). Solid lipid nanoparticles for parenteral 
drug delivery, Adv. Drug Deliv. Rev. 56, 1257-1272. 
Wrich L, Vito La F, Jorge P., 1998. Upregulation ofendothelial nitric oxide synthase by 
HMG-COA reductaseinhibitors.Circ, 1998; 97: 1129-35. 
Xiangjian Z., Wendy B., 2003. Aquaporin 3 Colocates with Phospholipase D2 in 
Caveolin-Rich Membrane Microdomains and Is Downregulated Upon Keratinocyte 
Differentiation. Journal of Investigative Dermatology; 121:1487–1495.  
  
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE 
 

